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The CRS Newsletter—A 21st Century Transition 
Effective January 2016, the CRS Newsletter will be digital only. The electronic 
CRS Newsletter is one of the most popular member benefits. The cost and 
environmental footprint associated with printing the newsletter and mailing it 
across the globe six times a year are substantial. With the transition to digital, the 
society realizes a significant savings, reduces its environmental impact, and meets 
members’ interests. With this transition, CRS will provide members with more value, 
more connections, and more opportunities.
What Do We Have Now?
Several years ago, while vacationing in Door County, Wisconsin, I stepped into an art studio. Upon viewing several inspirational works, I struck up a conversation 
with the proprietor and asked for recommendations on inspirational artistic reading. 
Beyond my scientific discipline, I dabble in drawing and painting and had come into 
a dry spell. One recommendation was the book Art and Fear: Observations on the 
Perils (and Rewards) of Artmaking, by David Bayles and Ted Orland. 
I eventually read the work and am currently reading it again. It is filled with 
philosophical thoughts on artmaking and what makes an artist. It expands on 
concerns such as whether it is possible to pretend to be an artist, what talent is, and 
the dangers of seeking perfection (which is both undesirable and unattainable). Two 
thoughts from the treatise are currently circulating in my mind: 1) the statement 
“whatever you have is exactly what you need to produce your best work” and 2) a 
focus on quantity yields quality. 
Whether an interest is art, science, business, or any combination, we are all entrusted 
with an aptitude and circumstance to develop and nurture. Our best work at this 
point is related to what we have at this point. Hopefully, it is an improvement over 
what we had in the past and the future will be an improvement over what we have 
now. Our collective and shared interactions in CRS and other spheres of influence are 
a part of what we have and help set the bar for what is our best. 
This thought is echoed in the balance of quantity and quality. Artists focused on 
quantity yield better quality work than those focused on quality. Quantity expands 
the scope of experimentation, knowledge, and skill needed to optimize quality. The 
expanding and accelerating pace of today’s scientific work is adding to our knowledge 
base at an ever-increasing rate, which accelerates our understanding of the physical 
world and the means to address our challenges. 
I encourage you to take time to peruse this sixth and final issue of the 2015 CRS 
Newsletter. It is one element of this vibrant society and a means to see what we have, 
what our best is, and how you can contribute to the quantity and quality of controlled 
release science. 
I wish you all the best as 2015 comes to a close and the 2016 chapter begins! 
Chuck Frey n
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3As the Annual Meeting Program Committee Chair, I’m excited to announce several changes for the 2016 Annual 
Meeting & Exposition in Seattle, Washington, U.S.A., 
July 17–20. We believe that our refinement of past program 
components and the addition of a few new elements will greatly 
benefit attendees. The meeting will commence on Sunday with 
the Opening Session/Award Ceremony, along with a plenary 
lecture and the Exhibition Grand Opening and Happy Hour. 
This will then be followed by three full days of solid scientific 
programming, ending late afternoon on Wednesday.
Given the overwhelmingly positive feedback received from 2015 
attendees, the scientific sessions will maintain the format used 
last year. Each session will consist of one or two invited speakers 
followed by several Research Highlight Talks (a five-minute 
podium presentation with a corresponding poster) and a 
moderated discussion. However, the topics of the scientific 
sessions have been changed to more accurately reflect the diverse 
research and industry topics of current member interest and 
importance. There will be four concurrent sessions each day. In 
addition, the program continues to include sessions dedicated to 
topics of the Consumer and Diversified Products (C&DP) and 
Preclinical Sciences and Animal Health (PSAH) Divisions. The 
2016 Annual Meeting & Exposition will combine the best 
features from past meetings with these unique elements:
•	 A total of 21 sessions divided by delivery routes, such as oral, 
parenteral, transdermal, and ocular. 
•	 Hot Topic Sessions and Roundtables focused on industry 
needs. 
•	 A session highlighting the future of drug delivery systems: 
“Thinking Outside the Box” Delivery Technologies: 
Nanocarriers from Nature.
•	 A focus on critical areas of current interest to the delivery 
science and technology community. 
•	 Sessions providing reflection on the current status of drug 
delivery: “Where are we, and are we telling it straight?”
Another unique feature of the 2016 program is the introduction 
of a Poster Pub session offered on Monday. This session is 
designed to further highlight the poster presentations with an 
exchange of ideas over light refreshments. This year, we have also 
increased the number of Research Highlight Talks to provide 
more presentation opportunities. These five-minute talks give 
attendees a snapshot of science and technology research to spark 
innovative partnerships and scientific brainstorming. Overall, 
attendees will have the chance to immerse themselves in more 
than 150 podium presentations!
We look forward to welcoming you to the 2016 CRS Annual 
Meeting & Exposition. Please join us in making this the best 
CRS meeting yet!
Please note: abstracts close January 15, 2016. There is a new 
one-page abstract format. Keep apprised of the latest news via 
CRS e-communiques or join the Controlled Release Society 
LinkedIn Group. n
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42016 CRS Annual Meeting Session Topics
Comparative Pharmacokinetics in Preclinical 
Sciences. Preclinical science and animal models are key compo-
nents in determining pharmacokinetics and pharmacodynamics 
of new drugs and delivery systems. Preclinical data obtained 
across species drives initial candidate drug design/selection and 
resultant optimization of development procedures needed for 
regulatory approval. This session will address how to design pre-
clinical studies in select animal species. First, in silico modeling of 
data from administration routes will be examined relative to the 
target species, and second, the increasing complexity of designing 
dissolution studies in media relevant to true intestinal conditions 
will be discussed.
Delivery Technologies in Cosmetics, Personal 
Care, and Household Products. This session will cover all 
aspects of controlled release in personal and home care areas. 
Examples are cosmetics, cosmeceuticals, skincare, fragrances, 
deodorants and antiperspirants, hair care, mouth care, air freshen-
ers, cleaning and sanitizing agents, and insect/pest/mold control 
agents and devices. This core area seeks to promote progress and 
applications across this diverse range of products, with particular 
emphasis on the research and manufacturing activities ongoing in 
the relevant industries. 
Delivery Technologies in Nutraceuticals, Food, 
and Oral Products. This session will include all aspects of oral
delivery science and product development, including immediate, 
sustained, delayed, and pulsed release. It includes oral delivery of 
drugs (from small molecules to biologics), food, feed, beverages, 
nutrients, nutraceuticals, flavors, probiotics, prebiotics, and sup-
plements. Topics of interest are broad and include, but are not 
limited to, all aspects of systems that enhance oral absorption, 
introduce prolonged effect and stability of additives, product 
acceptability (including taste masking, rheology, etc.), targeted 
and/or more uniform delivery in the gastrointestinal tract, in vitro 
and in vivo models, analytical chemistry, formulation technology 
for poorly soluble agents, biopharmaceutics, equipment design, 
and computational modeling. 
Encapsulation and Controlled Release for 
Industrial Applications. This session focuses on advances in 
encapsulation and controlled release products in agrochemicals, 
agriculture, aquaculture, textiles, and other industrial applications. 
Topics include, but are not limited to, more efficient biomass pro-
duction for biofuels, genetic engineering (release of genetically 
engineered materials, enhancing organisms), anticorrosive and/or 
antifouling coatings (e.g., fish farms or offshore installations), 
self-healing coatings and materials (e.g., textiles), water storage 
systems, technologies for high-rise systems (fertilizing, light con-
trol), and more traditional areas involving controlled release of 
nutrients, vaccines, fertilizers, and pesticides. 
Local Drug Delivery. With increasing awareness 
of challenges in systemic drug delivery and recent advances in 
imaging technologies, local drug delivery is revisited as a promis-
ing means to achieve target-specific drug delivery. This session 
covers new formulation technologies exploiting accessible local 
routes for target-specific drug delivery—such as lungs, eyes, nose, 
oral cavity, gastrointestinal tract, vagina, and peritoneal cavity—
featuring clinical and industrial perspectives.
Manufacture, Characterization, Stability, and 
Regulatory Aspects. This session will cover technology 
development through scale-up of commercially viable processes 
and methods to prepare and characterize products designed for 
controlled release of active materials. Some examples of process 
technologies include spray-drying, hot-melt extrusion, co-precip-
itation, supercritical fluid technology, fluid bed coating, complex 
coacervation, 3D printing, inkjet printing, electrospinning, 
microfluidics, powder layering techniques, high-shear granulation 
techniques, membrane processes, and emulsion-based processes. 
The use of quality-by-design (QbD) concepts, analytical tech-
nologies for process end-point and real-time monitoring of 
preparation processes, imaging methods, and other approaches 
to ensure commercial viability are also critical to this area.
New Processes, New Materials, New Products. 
New manufacturing processes can lead to both new materials and 
new systems and hence new products. Sometimes new processes 
are, like electrospinning, old but have been more recently adopted 
because of the availability of appropriate materials and adapted 
technologies to produce new forms (such as fibers) with potential 
for drug delivery in more versatile ways. Two- and three-dimen-
sional printing techniques are a case in point. This session will 
consider production techniques such as these but also new mate-
rials such as graphene and graphane analogues, magnetic sur-
factants, or other materials that allow more precise design and 
novel uses.
Ocular Drug Delivery. Ocular drug delivery has been 
a major challenge to drug delivery scientists owing to the
 complex anatomy and physiology of the eye. In addition, the 
demonstration of bioequivalence for generic ophthalmic products 
to their reference products can be challenging. This session will 
focus on the recent advances in ocular drug delivery with an 
emphasis on new materials for long-acting products that can 
be used to deliver both small and large molecules. This session 
will also highlight general recommendations for establishing 
bioequivalence of generic ocular drug products including in vitro 
approaches.
The 43rd CRS Annual Meeting & Exposition will be where delivery science and innovative technol-
ogy connect! Join industry and academic leaders from across the globe exploring, presenting, and 
discussing the best in delivery science and technology innovations. The 2016 meeting features 
three full days of scientific programming, in-depth sessions to immerse you in science that reflects 
your interests, more opportunities to network with colleagues, and an exhibit hall with the latest 
products and services to help you find solutions. Submit your abstract today!
5Oligonucleotide Delivery: New Applications 
and Opportunities. This session focuses on therapeutic 
approaches utilizing oligonucleotides including antisense 
oligonucleotides, siRNAs, and miRNAs. The session will high-
light innovative chemistry (e.g., conjugate) and formulation-based 
delivery systems and therapeutic approaches requiring access to 
tissues and cell types outside of the liver. Novel approaches for 
targeting both actively (e.g., with targeting ligands) or passively 
(e.g., endogenous targeting approaches) will be discussed as well 
as approaches for efficient intracellular delivery. Immunomodula-
tory applications will also be highlighted. 
Oral Delivery. This session focuses on advances in 
delivery science and technology for both systemically and locally 
acting oral formulations. This session will highlight the impact of 
key excipients on manufacturing, quality, and clinical performance
of oral drug delivery systems. This session will also highlight the 
recent developments in locally acting gastrointestinal drugs with 
an emphasis on how to determine local drug dissolution. In 
addition, this session will highlight the efforts that have been 
made by industry, academia, and regulatory agencies to ensure 
the therapeutic performance of advanced oral drug delivery 
systems including amorphous solid dispersions and modified 
release drug products.
Overcoming Biological Barriers in Drug Delivery. 
Biological barriers were created during evolution to enable 
organisms to precisely control the interaction between inside and 
outside environments. The differentiation at interfaces to regulate 
water homeostasis, uptake of nutrition, gas exchange, or exchange 
of waste is manifold and constitutes a key hurdle in the field of 
drug delivery. This session will highlight advances in drug delivery 
through biological barriers that include, but are not limited to, 
the blood-brain barrier, blood-ocular barrier, mononuclear 
phagocyte system, tissue penetration barriers, cell uptake barriers, 
and intracellular barriers.
Parenteral Systemic Delivery of Biopharmaceuti-
cals: Overcoming Product Development and Regulatory 
Challenges. This session will focus on current hot topics in the 
development of injectable biopharmaceutical products including 
formulation, delivery, stability, and regulatory considerations criti-
cal in advancing novel delivery based biopharmaceutical products 
to the clinic and commercialization. In addition, the session will 
highlight current approaches for the characterization of parenteral 
delivery systems and the bioactives contained within them, 
especially those of importance to regulatory agency approval.
Peptides, Proteins, and Vaccines. The global
medicines market is undergoing a period of dramatic change, and 
it is forecast that by 2016 biopharmaceuticals will overtake small 
molecules’ domination of the market. While biopharmaceuticals 
(including peptides, proteins, and vaccines) offer unique modes of 
action, which are highly specific with far fewer side effects, their 
commercialization requires significant innovation. This session 
will focus on strategies to maximize therapeutic effectiveness of 
peptide, protein, and vaccine formulations, including topics on 
formulations/devices/technologies that (1) improve targeted 
delivery, (2) enhance immunization efficacy, (3) minimize delivery 
invasiveness or increase patient adherence, (4) extend and control 
release, (5) enhance stability, and (6) lower development and 
manufacturing costs.
Physical Oncology: Modulating Tumor 
Microenvironment for Drug Delivery. The discrepancy 
between preclinical and clinical outcomes arises, in part, owing 
to the failure of conventional model systems to recapitulate the 
complexity of solid tumor tissues. One major factor in the com-
plexity of tumors is their fibroinflammatory component (stroma), 
which increases tumor interstitial fluid pressure, blocking the de-
livery of anticancer therapies to tumor cells, and contributes gen-
erally to chemoresistance. This session focuses on advances in the 
delivery of drugs deep into tumor tissues achieved through modu-
lation of components of the tumor microenvironment. Efforts that 
target the biophysical barriers to perfusion, diffusion, and convec-
tion imposed by the desmoplastic reaction will be highlighted.
Preclinical Science Challenges to Drug Delivery.
How drug distribution occurs in different species is related in 
part to structure and function of drug transporters, and these can 
have a bearing on behavior of drug delivery systems in preclinical 
animal models. An alternative approach in preclinical research is 
the advances made in 3D cell culture models as well as organ-on-
a-chip models of human and animal tissue. Apart from contrib-
uting positively to the three Rs (replacement, reduction, and 
refinement), these models have improved metabolism predictive 
capacity and also can be used to interrogate drug target 
interactions, as well as to screen drug candidates efficiently. 
Predictive Modeling in Delivery and Targeting
(Scaling: Mouse to Man; Probability of Reaching 
Targets; Stochastic Process in System Distribution). 
Mathematical modeling of drug delivery and targeting provides 
opportunities to reduce empiricism in our science. To achieve this 
we must have predictive models of the behavior of systems such 
as nanoparticles in vivo. There is a need for understanding the 
scaling factors in extrapolation from animal models to humans, 
and for evaluation of the mathematical probability of issues such 
as extravasation and binding to receptors, including a realization 
of the stochastic nature of many of the processes in targeting. This 
session will survey some approaches to allow the next generation 
of delivery systems to be designed more rationally.
Taking Stock of Progress and Challenges in Drug 
Delivery and Targeting. It is crucial after decades of research 
into new drug delivery and targeting systems that we reflect on 
true progress and define honestly the challenges that lie ahead. 
This session asks two questions: “where are we now?” and “are we 
telling it straight?” These questions apply not only to nanotechnol-
ogy but also to instances wherein our science has translated into 
false promises. There is often a lack of quantitative data on the 
delivery of the active let alone the carrier to putative targets, and 
few papers discuss target pharmacokinetics let alone particokinet-
ics. Contributions that address these issues are welcome.
Annual Meeting Session Topics continued on page 6
2015 CRS Annual Meeting 
Plenary Webcasts Now Available
Free education for members
Free education is just a click 
away! Log on now to access 
these plenary sessions and more!
Customized Drug Delivery: A Personal Odyssey
Vincent H. L. Lee 
Chinese University of Hong Kong
Intelligent Polymer Hydrogels: From Obscure 
Molecular Structures to Useful Multifunctional 
Systems for Drug and Protein Delivery, Targeting, 
and Molecular Sensing 
Nicholas A. Peppas 
The University of Texas at Austin
Global Efforts and Successes in Needle-Free 
Peptide Delivery
Maria José Alonso 
University of Santiago de Compostela
Integration of Imaging and Drug Delivery. 
In recent years, there has been tremendous effort to integrate 
imaging and drug delivery in order to improve therapeutic 
response and clinical outcomes. In particular, emphasis has been 
placed on exploiting imaging to deepen our understanding of 
drug and delivery vehicle transport, to guide interventions that 
enhance drug delivery, and to identify subpopulations of patients 
that are likely to respond to a specific therapy. This session will 
highlight exciting advances in this area of research with an em-
phasis on approaches that have advanced to late-stage preclinical 
or clinical development. Challenges in the clinical translation and 
development of image-guided interventions will be discussed.
“Thinking Outside the Box” Delivery Technolo-
gies: Nanocarriers from Nature. Living creatures have 
developed diverse bioactive materials with unique structures to 
survive and adapt to changing environments. This session will 
highlight two groups of natural nanocarriers, namely, exosomes 
and protein nanocages. Exosomes are nanometer-sized membra-
nous vesicles that play a major role in intercellular communication 
owing to the ability to transfer proteins and nucleic acids from 
one cell to another. As a result, there has been significant interest 
in exploiting exosomes for applications in drug delivery. Nature in 
its wonders presents the most intricate and delicate protein struc-
tures, including those of cage-like architecture. Perfect and com-
plex symmetry is ubiquitous in protein nanocages, and they can 
be engineered for applications in drug delivery. This session will 
largely highlight exosome and protein nanocage-based delivery 
strategies, with additional emphasis on drug delivery technologies 
formed from other natural materials.
Tissue Engineering. Tissue engineering that aims
to recreate functional tissues and organs has emerged as a 
promising strategy to treat a series of tissue defects, to create 
in vitro cell culture platforms, and to engineer biological machin-
ery. Despite the impressive results reported over the past decades, 
there is still a real need to improve the quality of engineered tissue 
by regulating transport and bioactivity of regenerative medicine, 
including incorporation of synthetic drug molecules, growth 
factors, DNA, and so on. To this end, this session will discuss 
current efforts and future directions to utilize and further modify 
advanced drug delivery technologies for enhanced tissue
engineering in both academia and industry.
Transdermal Delivery. Transdermal delivery 
constitutes a popular alternative route of administering drugs. 
This session will cover new developments in all aspects of 
transdermal drug delivery, including understanding of transder-
mal permeation pathways, especially for macromolecules. 
Contributions on the development of devices and formulations 
to enhance transdermal drug delivery are welcome. Contributions 
reporting clinical translation of technologies are of particular 
interest. Novel analytical tools to study transdermal drug delivery 
and mathematical models for describing transport are also 
welcome. This session will also include new developments in 
topical drug delivery methods that focus on localized delivery of 
small and large molecules such as peptides and nucleic acids. n
Present your research at the 2016 CRS Annual 
Meeting—submit an abstract by January 15, 2016.
Annual Meeting Session Topics continued from page 5
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Special Feature
The 42nd CRS Annual Meeting & Exposition was held at the 
International Conference Centre, Edinburgh, Scotland, July 26–
29, 2015. Prior to the meeting, the premeeting Ocular Drug 
Delivery workshop, held on July 25, aimed at bringing together 
leading researchers from both academia and industry to share 
challenges and present recent approaches to deliver actives to the 
front as well as the back of the eye. Seventy-one attendees from 
academia and industry registered to listen to four speakers from 
academia and five from industry, as well as another four 
company presentations. The workshop was sponsored by Envisia 
Therapeutics, Novaliq GmbH, Genentech, Phoenix Research 
Labs, pSivida, GrayBug, and Ora. 
The day started with a warm welcome by the chairs and 
organizers of the workshop, Ilva Rupenthal from the University 
of Auckland, New Zealand, and Michael O’Rourke from Scotia 
Vision Consultants, U.S.A. Ilva then kicked off the academic 
talks by providing a general overview of drug delivery 
approaches to the front and back of the eye, highlighting the 
limitations of current delivery technologies as well as the need to 
understand drug pharmacokinetics in order to accelerate the 
development process for emerging technologies. Arto Urtti from 
the University of Helsinki, Finland, then focussed on 
pharmacokinetic modelling and the limiting factors in 
developing predictive pharmacokinetic and pharmacodynamic 
models to evaluate ocular drug delivery approaches and follow 
the fate of the administered active.
1  Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, 
New Zealand National Eye Centre, Faculty of Medical and Health 
Sciences, University of Auckland, New Zealand.
2  Scotia Vision Consultants, Tampa, Florida, U.S.A.
Ocular Drug Delivery: Challenges of Matching
New Technologies with Drug Pharmacokinetics
M. Naveed Yasin,1 Ying-Shan Chen,1 Di Huang,1 Priyanka Agarwal,1 Michael O’Rourke,2 and Ilva Rupenthal 1
Carrying on with the talks after a short morning tea break, 
Rocío Herrero-Vanrell from the Universidad de Complutense, 
Spain, presented on intraocular delivery of biodegradable 
microspheres to achieve sustained delivery of actives and thus 
reduce the frequency of administration, increasing patient 
compliance. Rocío covered recent publications from her group 
including the benefits of encapsulation into microspheres with a 
focus on additives used to further sustain delivery and enhance 
the stability of the actives. “Engineering Biomaterials for Ocular 
Applications” was the topic presented by Heather Sheardown 
from McMaster University, Canada, highlighting the progress of 
her group to use contact lenses as effective delivery devices for 
proteins and various other actives. She also presented on a smart 
implantable drug delivery system that can be activated by light, 
thus controlling the drug release non-invasively. Ann L. 
Daugherty, Senior Manager of Drug Delivery at Genentech Inc., 
U.S.A., was the first industry speaker and presented the 
challenges and successes of delivering protein therapeutics to the 
back of the eye. Focusing on various approaches to enhance 
efficient delivery of actives to the back of the eye by formulation, 
chemical modification, and device-based approaches, she urged 
scientists working in the field to consider aseptic compounding 
requirements and ocular tolerability of novel materials and 
devices at an early development stage. 
After a delicious and well-earned lunch, the afternoon session 
kicked off with four company presentations. Stuart Williams 
from Envisia Therapeutics, U.S.A., talked about ENV515 and 
ENV905, two biodegradable devices based on the proprietary 
PRINT® technology that can provide sustained drug delivery 
over extended periods. This was followed by a talk from Dieter 
A full house at the Ocular Drug Delivery workshop with 71 attendees.
Workshop chairs and organizers Michael O’Rourke and Ilva Rupenthal.
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9Scherer, Novaliq GmbH, Germany, who discussed their novel 
semifluorinated alkane technology, a non-aqueous vehicle that 
can improve formulation aspects and delivery of various actives. 
Dieter briefly touched on current products in the pipeline while 
highlighting the advantages of these novel vehicles to increase 
stability, solubility, and sterility of ocular formulations. Carrying 
on the company presentations, Scott Johnston from Phoenix 
Research Labs, U.S.A., presented on their Micron IV system 
designed to support eye research in laboratory animals. This 
retinal microscope produces high-quality digital fundus images of 
rodents and small animals for in vivo observations with 
capabilities in bright field, angiography, and fluorescent imaging. 
It can be acquired as a retinal imager alone or combined with 
optical coherence tomography, an image-guided laser for creating 
choroidal neovascularization (CNV), and/or with an image-
guided focal electroretinogram (ERG) to measure retinal 
functionality. The final company presenter was Jeff Cleland, who 
presented on GrayBug’s proprietary poly(lactic-co-glycolic acid) 
(PLGA) technology that causes minimal inflammation when 
degraded in the eye compared with conventional PLGA. Jeff 
talked about the injectable formulations in the pipeline fabricated 
from this proprietary PLGA to achieve sustained drug delivery 
in the treatment of ocular conditions such as wet age-related 
macular degeneration (AMD), glaucoma, and corneal graft 
rejection.
“Market Dynamics and Overview of Recent Developments in 
Industry” was the topic presented by Michael O’Rourke. Michael 
briefly covered the history of intravitreal devices for sustained 
delivery of actives to the posterior segment of the eye. He also 
highlighted recent financial figures revealing the shift from the 
anterior to the posterior segment of the eye and touched on the 
cost of developing a novel active compared with that of 
improving the delivery of existing actives by novel delivery 
technologies, emphasizing the market shift toward such delivery 
technologies. Andy Whitlock from Ora Inc., U.S.A., an 
independent ophthalmic contract research organization (CRO), 
Ann L. Daugherty discussing the importance of ocular tolerability of novel 
materials. On stage from left to right: Ilva Rupenthal, Michael O’Rourke, 
Andy Whitlock, Dieter Scherer, Paul Ashton, and Eugene de Juan.
then talked about the preclinical development of ocular drug 
delivery technologies emphasizing the important factors to be 
considered for successful commercial development. Following 
that, Eugene de Juan from ForSight Labs, U.S.A., shared his 
experiences in the translation of an ocular drug delivery device 
from the laboratory to clinical trials, highlighting important 
considerations and discussing “what it actually takes.” The last 
presentation of the workshop entitled “The Complete Story—
Going Through Regulatory Approval” was presented by Paul 
Ashton from pSivida Inc., U.S.A. Paul talked about his personal 
experience and involvement in the development of Vitrasert®, the 
first FDA-approved intravitreal device for sustained delivery of 
ganciclovir in the treatment of cytomegalovirus (CMV) 
infection. He also briefly described the most recently FDA-
approved intravitreal device, Iluvien™, which is based on the 
Durasert™ technology and delivers sufficient amounts of drug 
over three years in the treatment of diabetic macular edema.
The meeting concluded with a panel discussion with all 
presenters gathering on stage and answering any questions 
related to their presentations. This triggered a constructive 
discussion, which was continued by speakers and workshop 
attendees over a glass of wine. Overall, the workshop was 
considered a great success, and we hope to offer similar events 
focussed on ocular drug delivery again in the near future. n
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containing 150 mM NaCl) was used as the release medium in 
both the donor and the acceptor phases. The volumes in the donor 
and acceptor compartments were 3 and 52 mL, respectively. 
To evaluate the mathematical model, 1.5 mL of the free API 
(13.78 µg/mL) was dispersed in the donor phase. After 1.5, 3, 
and 4.5 h, 1.5 mL of the donor phase was replaced with 1.5 mL 
of the API solution (13.78 µg/mL). Data were processed by the 
four-step model that is described below and compared with the 
theoretical values. 
For dissolution testing, NPs before and after a purification 
procedure were contrasted to free drug as a reference (Figure 2). 
Data obtained from the DREAMS were further processed by 
the model to exclude the impact of membrane kinetics on final 
results for the drug release. 
Mathematical Theories
To apply the model to the experimental results, four steps are 
involved to process data obtained from the measuring system. 
Step One: Determination of the drug permeability constant (km). 
For a system agitated in the donor and acceptor compartment, 
the diffusion process can be described by Fick’s law,3 
(1)
where km denotes the drug permeability constant of the dialysis 
membrane. Ca and Cd are the concentrations in the acceptor and 
donor phases, respectively. Va denotes the dissolution volume of 
the acceptor phase. δ and A denote the thickness and the surface 
area of the membrane. 
When a certain amount (Q0) of free API is dispersed into the 
donor phase in a closed system, 
   (2)
Vd denotes the dissolution volume of the donor phase. Replacing 
Cd(t) in equation 1 and solving the equation analytically yields 
the following: 
 (3)
Equation 3 can be applied to fit the experimental data on free 
API passing through membrane to obtain km. 
 
Step Two: Computation of the concentration rate in the acceptor 
phase (∆Ca/∆t). A continuous profile of Ca(t) can be obtained by 
Introduction
The past two decades have seen rapid advances in applying 
nanoparticles (NPs) as drug delivery systems. A variety of 
experimental methods have been reported to study drug release 
from NPs. However, owing to the miniscule dimension of NPs, 
an optimal dissolution method appears to be challenging. 
Although one of the most common methods, the sample-and-
separate method suffers from disadvantages, such as premature 
release caused by the centrifugation and laborious sampling 
procedures. Alternatively, the application of dialysis membranes 
for sample separation has been introduced to release testing of 
pharmaceutical products. Typically, the release profiles measured 
from the acceptor phase have been reported as the cumulative 
drug release from the nanoparticulate system. Yet permeability 
through the dialysis membrane was discussed to be a rate-limiting 
step and could be responsible for a number of misleading results.1
In our recent study on drug release from NPs, a drug release 
automatic monitoring system (DREAMS) developed in-house 
was used to monitor the release process continuously by a 
fluorescence spectrometer. A four-step mathematical model 
adding up the released drug in both donor and acceptor phases 
was introduced to overcome the typical shortcomings of dialysis-
based approaches. To assess the method, an experiment was 
designed introducing the free drug in the donor phase at different 
time points with known amounts. Also, Eudragit® RS 100 NPs 
that were loaded with a photosensitizer served as the model 
formulation for the establishment of dissolution testing and the 
quantification model.2
Experimental Methods
The DREAMS setup was built in-house, consisting of two 
compartments: a dialysis cell and a measuring cell (Figure 1). For 
the dialysis compartment, a cellulose ester membrane (molecular 
weight cut-off: 50 kDa) was used to separate the NPs from the 
released drug. A magnetic stir bar was placed in the base of the 
acceptor compartment to agitate the fluid inside and outside the 
chamber. A continuous flow (2 mL/min) of the acceptor medium 
was ensured by pumping the fluid into the measuring cell, where 
the concentration of active pharmaceutical ingredient (API) was 
determined spectrometrically by a charge-coupled device (CCD) 
microspectrometer. A blue LED (peak wavelength 405 nm) was 
adapted as the fluorescence excitation for the API. The suspension 
of photosensitizer-loaded Eudragit® RS 100 NPs was injected 
into the donor phase. Phosphate buffer (pH 6.8, 20 mM, 
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the setup. Therefore, equation 1 can be expressed numerically,
 (4)
Step Three: Computation of the concentration profile in the donor 
compartment, Cd(t). Cd(t) can be computed from equation 4 with 
all parameters (km, Va = 3 mL, A = 8.0 cm2, and δ = 80 µm) known: 
 (5)
Step Four: Adding up the total accumulated amount of released 
drug in both compartments. Adding together Cd(t)×Vd and 
Ca(t)×Va results in the total released amount of the API. Qr(t) 
represents the total amount of free drug in the system: 
 (6)
Results and Discussion
The concentration in the acceptor phase was monitored (Figure 
3), and the sampling procedure of replacing the liquid in the 
donor phase was undertaken at the defined time points. A 
concentration profile of the donor phase was computed using 
equation 5, indicating that the changes of concentrations in the 
donor phase reflected the impact of the replacement procedure. 
By multiplying the related volumes, the drug amounts in both 
compartments were summed up and found to be in accordance 
with the theoretical values. This feature shows that DREAMS is 
able to monitor the initial burst of drug release kinetics. 
Dissolution testing was carried out to investigate NP suspensions 
with or without a purification procedure. Free drug experiments 
were carried out to determine the permeability constant km by 
fitting to equation 3, and (1.8 ± 0.093)×10–3 cm2/h as km ± SD 
was determined.
As seen in the Figure 4A, it is apparent that the system was able 
to discriminate the three types of samples. The experimental 
Figure 1. The schema of the specially designed apparatus for dissolution 
testing of NPs. A dialysis membrane was used to separate the NPs and 
released API. The concentration in the acceptor phase was monitored 
continuously by a home-built fluorescence spectrometer. ©Elsevier, reproduced 
with permission.4
Figure 2. The composition of different samples. Free drug was used as the 
control. Purified NPs, which only contain encapsulated drug in the NPs, were 
tested relative to the unpurified NPs.
Figure 3. Free API was replaced in the donor phase at 1.5, 3, and 4.5 h 
(shown as arrows). Data monitored in the acceptor phase were normalized by 
the total amount of the photosensitizer in the system (blue line). Computed 
API fraction in the donor phase (orange line) using the four-step model. The 
main figure shows the total amount of free API in the system processed by the 
model (black line), which is in comparison with theoretical values (grey 
dashed line).
Figure 4. The results of free drug (blue line), unpurified NPs (orange line), 
and purified NPs (green line). (A) Normalized by the peak value of the raw 
data measured by DREAM. (B) The numerical values of dCa/dt (equation 
4). ©Elsevier, reproduced with permission.4
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results were also highly reproducible. For step two of the model, 
Figure 4B presents the computational results of numerical values 
of dCa/dt. The slower rate in the decrease of unpurified and 
purified samples suggested a continuing release of the drug from 
NPs. 
Using equation 5, the concentration profiles in the donor 
compartment can be obtained (see Figure 5). The results were 
then normalized by the cumulative drug release measured by 
HPLC. As Figure 5B presented, there was a steady increase in 
the concentration in the donor compartment of purified NPs. 
Unlike purified NPs, unpurified samples (Figure 5C) reached 
the peak concentration in the donor compartment almost 
immediately after the experiments began, which indicates a 
certain amount of free drug initially in the samples.
Figure 6 presents the corrected release profiles after applying 
step four of the mathematical model. For the control 
experiment, the amount of free API in the system remained 
unchanged throughout the experiment. It also shows that the 
purified samples underwent a more sustained release relative 
to unpurified ones, which can be explained by the higher 
amount of NPs contained in the samples. Interestingly, the 
y-axis interceptions of the three groups indicate the initial 
amount of free drug in the system (both donor and acceptor 
compartments). This can be beneficial for the quality control 
purpose for drug preparation. 
Conclusion
The current study has demonstrated an innovative apparatus for 
dissolution testing of nanosized dosage forms. The feasibility of 
the approach was successfully tested on the 
free drug and drug release from NPs (with or 
without a purification procedure). The system 
together with the four-step model was able to 
study the drug release quantitatively regardless 
of the rate-limiting step caused by the mem-
brane. Moreover, the novel method can be 
applied to quantify the initial amount of 
free drug in the sample, which is usually 
challenging for conventional methods 
sampling noncontinuously. 
This work can be further adapted to other 
model particles for dissolution testing to 
facilitate the tedious and laborious sampling 
procedures as well as to obtain quantitative 
results. 
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Introduction
The concept of personalized medicine implies the treatment of 
each single patient as a unique subject,1 thus overcoming the old 
idea of the average patient. This strategy, via an optimized dosing, 
is greatly beneficial for the patient, because it allows the reduc-
tion of side effects and the improvement of the effectiveness of 
the therapeutic treatment. On the other hand, it poses the not 
negligible problem of patient uniqueness. Indeed, uniqueness 
requires the definition of a rational approach that can be fitted to 
each patient. For this purpose, mathematical models, defined as a 
mathematical metaphor of some aspects of reality,2 can be of 
great utility.3 Of course, to represent a reliable and effective theo-
retical tool in the field of personalized medicine, the mathemati-
cal model must account for the most important aspects of drug 
release and the absorption, distribution, metabolism, and excre-
tion (ADME) processes. Moreover, it is mandatory to account 
for the simultaneous time evolution of drug release and ADME, 
processes that are not independent but mutually affect each oth-
er. This requirement reflects the conviction that the new chal-
lenge in the drug delivery field, for what concerns mathematical 
modeling, resides in the possibility of developing mechanistic 
theories able to consider together drug release and ADME phe-
nomena within the human body.4
Accordingly, this work focuses attention on the bridging role 
played by the drug mass balance between drug release and 
ADME processes. Indeed drug mass balance represents the 
theoretical tool that enables accounting for the simultaneous 
development of drug release and ADME processes. Notably, the 
mathematical expression of the overall model (drug release plus 
ADME) will depend on the different administration routes and 
drug delivery systems considered. Indeed, depending on these 
two aspects, different phenomena will play the role of key factors 
in determining drug pharmacokinetics (PK). However, the 
validity of the mass balance approach holds regardless of the 
administration route and the drug delivery system considered. 
The only requirement for this approach is that all the equations 
used to build up the model are expressions of local mass 
balances.5
Mathematical Modeling
During release, the drug is absorbed by the surrounding tissues 
and blood and then, eventually, it spreads into less perfused 
tissues and organs. Thus, the first part of the model has to deal 
with the release step, that is, with the factors affecting drug 
release such as swelling, erosion, drug dissolution (possibly 
recrystallization), drug transport (by diffusion and convection), 
drug interaction with the delivery system structure, osmotic 
pressure, and system geometry.3 The usual way to deal with this 
part of the model consists in adopting the local mass balance 
referred to the moving species (typically, drug and the 
physiological fluid):
(1)
where the expression of Fi, the matter flux, is dictated by the 
most relevant factors ruling the release kinetics. The 
mathematical modeling of the ADME steps is usually 
performed by means of ordinary differential equations expressing 
the time variation of the drug concentration in the different 
sections, or compartments, into which the human body can be 
subdivided:6 
(2)
Regardless of the specific choice adopted for the body 
subdivision into compartments, it is mandatory that each 
differential equation is an expression of the time-dependent drug 
mass balance referred to the pertinent compartment. Indeed, if 
this were not the case, it would be impossible to link the two 
model parts (drug release and ADME) by means of the bridge 
(i.e., the drug mass balance carried out on the whole body):5
(3)
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Equation 3 simply states that, at any time, the 
sum of the drug mass present in the release 
environment (VrCr), in the delivery system 
(VRSCRS), and in the NC compartments (VjCj), 
plus the drug amount recrystallized (Mc) and 
eliminated or metabolized (Mel) must be equal to 
the administered dose (M0). 
Results and Discussion
Different delivery systems and administration 
routes were considered. In particular, attention 
was focused on oral administration of drug-
loaded spheres. 
Figure 1A shows the best fitting (solid line) of a 
mathematical model based on equations 1–3. 
Red dots represent the experimental plasma 
concentration (Cp) of nimesulide, a typical 
nonsteroidal anti-inflammatory drug. These data 
refer to the oral administration (three humans) 
of a commercial prompt-action formulation 
containing nimesulide (100 mg) in crystalline form. Relying on 
this fitting and on literature PK data about nimesulide, it is 
possible to simulate the Cp trend (orange line), assuming that 
nimesulide is completely amorphous inside the delivery system. 
Indeed, the solubility of amorphous nimesulide is considerably 
higher than crystalline nimesulide. Figure 1B shows the 
theoretical concentration profile of nimesulide in the 
gastrointestinal lumen (Cr), assuming crystalline (black line) or 
amorphous (orange line) nimesulide. Interestingly, it can be 
noticed that the best performance of amorphous nimesulide 
implies a high concentration (orange line) in the stomach and in 
the small intestine within the first 12 min after administration. 
The rapid increase of Cr occurring after 1 h, in both the 
crystalline and amorphous case, is simply owing to the reduced 
value of drug permeability in the large intestine. Finally, Figure 
1C shows nimesulide concentration (CT) in the scarcely perfused 
tissues and organs. Drug concentration monotonically increases, 
reaching (for both the crystalline and amorphous case) values 
that are about two orders of magnitude smaller than Cp. Again, 
amorphous nimesulide implies a higher concentration with 
respect to that of crystalline nimesulide.
Figure 2A reports the simulated theophylline plasma 
concentration (Cp) according to a mathematical model based on 
equations 1–3. Simulations refer to the oral administration of 
100 mg of theophylline dispersed in an ensemble of all equal 
polymeric particles whose total volume is 1 cm3. In particular, the 
red, blue, and black lines refer, respectively, to particles 
characterised by a radius equal to 60, 600, and 6,000 µm. 
Obviously, the smaller the radius, the faster is the theophylline 
appearance inside plasma. Figure 2B reports the theophylline 
concentration in the gastrointestinal tract. The flat profile of the 
60 µm particles (red line) is simply due to the negligible 
permeability of theophylline in the gastric lumen. Accordingly, 
the drug initially keeps its maximum value, and it decreases only 
after getting into the small intestine, where theophylline 
permeability is of the order of 10–4 cm/s. Figure 2C makes clear 
that theophylline concentration in scarcely perfused tissues and 
organs (CT) is low in comparison to Cp and Cr. In addition, the 
60 and 600 µm particles are characterised by a similar CT trend.
Conclusions
The mass balance approach was demonstrated to be robust and 
versatile concerning the simulation of in vivo drug release and 
ADME processes. While the robustness refers to the model 
numerical solution, the versatility relies on the possibility of an 
easy improvement of the model by simply updating the 
mathematical interpretation of the release and the ADME parts.
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Figure 1. Modeling of nimesulide concentration: (A) plasma concentration; (B) concentration 
profile in the gastrointestinal lumen; and (C) concentration in the scarcely perfused tissues and 
organs.
Figure 2. Modeling of theophylline concentration: (A) plasma concentration; (B) concentration in 
the gastrointestinal tract; and (C) concentration in the scarcely perfused tissues and organs.
Scientifically Speaking Grassi continued from page 13
15
Young Scientist Committee Update
Jennifer Wong1 and Patrick Baumhof 2
Committee Corner
This year, the Young Scientist Committee (YSC) breathed fresh 
air into their variety of workshops, Get Up! Get Educated! 
sessions, roundtable discussion, the popular Mentor-Protégé 
Program, and a sell-out networking event. As expected, all the 
events were a great success, but two deserve special mention. 
The Saturday workshop is now interactive! The Young Scientist 
programme kicked off on Saturday with a workshop titled “The 
Rise, and Rise, of Precision Medicine.” Our three guest speakers 
were Devendra Pade (Simcyp Limited), Carlos Garcia-
Echeverria (Sanofi), and Heinrich Haas (BioNTech RNA 
Pharmaceuticals GmbH). All three had a range of industry 
experience and provided interesting insights into their view of 
how drug delivery platforms could be leveraged to take 
advantage of precision medicine strategies. The biggest hits 
seemed to be the interactive sessions between talks. The ice 
breaker at the beginning involved pairing people up and allowing 
one minute for both of them to introduce themselves, their 
research topic, and how their research could help the other 
person. This gave people the chance to start a conversation and 
engage with everyone in the room. It was great fun, and many 
attendees said they were able to recognise faces and say hi to 
people throughout the rest of the conference. Later, attendees 
were divided into groups, and they were asked to brainstorm and 
present a pitch on their vision of a precision medicine product 
1 University of Sydney, Australia.
2 CureVac AG, Germany.
The energetic Speed Mentoring Event at the CRS Annual Meeting.
Devendra Pade in close discussion with a group of young scientists.
that could make a difference. Our guest speakers had a 
wonderful time judging these refreshing concepts from the next 
generation of scientists, and members of the winning team took 
home tickets to the Lunch with the Luminaries. Afterward, the 
attendees also had the opportunity to discuss the prospects of 
precision medicine directly with the speakers in small groups.
The tables for your career development are turning (pun 
intended)! This year, the ever-popular Mentor-Protégé Program 
was reborn as the fast-paced and energetic Speed Mentoring 
Event. Up to 70 protégés were divided among ten tables, and 
mentors rotated through each table to provide protégés with 
guidance and career advice. The ticking clock meant that it didn’t 
take long for the room to be filled with the roar of voices as 
protégés enthusiastically asked questions to capitalise on the 
experience of mentors. Everyone thoroughly enjoyed the 
dynamic interaction, and the hour passed by in an instant. 
This year has been an amazing experience, and the YSC team are 
excited to bring even bigger and better things in the year ahead. 
Stay tuned for more! n
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Drug Delivery and Translational Research Update
Vinod Labhasetwar, Editor-in-Chief, Cleveland Clinic, Cleveland, Ohio, U.S.A.
Thanks to Authors, Reviewers, and Guest Editors
The editorial team of Drug Delivery and Translational Research 
(DDTR) and the Controlled Release Society are thankful to 
authors, reviewers, and special issue guest editors. Because of their 
efforts and contributions, we not only successfully completed five 
years of publication but maintained a high quality of published 
papers. Exclusively focused on translational aspects of drug 
delivery, DDTR provides a unique forum for publication of 
high-quality research with significance in drug delivery science 
and technology. Join the leading scientists who are publishing 
their work in DDTR. It is available online to CRS members as a 
membership benefit. The members must login to the CRS website 
first and then click the Publications tab to get to the member 
access link. 
In this issue of CRS Newsletter, I would like to acknowledge the 
guest editors who have developed 12 special issues. 
“Advances in Vaginal Drug Delivery,” with guest editor David 
R. Friend (CONRAD, U.S.A.), volume 1, issue 3, June 2011.
Vaginal drug delivery systems are gaining widespread interest 
because they allow the local administration of drugs to prevent 
transmission of sexually transmitted diseases such as HIV-1 
and HSV-2. These systems may also apply for contraception. 
This special issue describes various “multipurpose” drug 
delivery technologies for drugs of different physicochemical 
properties including peptides and vaccines, either alone or in 
combination, for a number of indications. Since sexually 
transmitted diseases are on the rise worldwide, an effective 
vaginal drug delivery technology could have global 
implications. 
“Advances in Image-Guided Drug Delivery,” with guest editors 
Arash Hatefi and Tamara Minko (Rutgers, The State University 
of New Jersey, U.S.A.), volume 2, issue 1, February 2012.
Image-guided drug delivery (IGDD) is an emerging 
therapeutic approach in which imaging modalities are used to 
guide and monitor localization of therapeutics to the site of 
action. Therefore, a methodical approach to IGDD entails 
systems for delivery, targeting, and monitoring (imaging) of the 
course of action. This special issue covers various technologies 
that are being developed for simultaneous drug delivery 
validation and therapeutic response evaluation in disease 
conditions.
“Drug Delivery to the CNS,” with guest editor Pericles Calias 
(Shire HGT, U.S.A.), volume 2, issue 3, June 2012.
Strategies for treating the central nervous system (CNS) 
manifestations of diseases have evolved well beyond the 
traditional size/lipophilicity paradigm. This special issue 
describes the challenges of developing therapies targeted to the 
CNS, from bench to clinical development. A review of the 
biological hurdles and current strategies for overcoming them 
sets the stage for discussions on the assessment of the product’s 
pharmacologic effect within the CNS and regulatory 
considerations for the incorporation of biomarkers into 
product development programs.
“Regenerative Medicine,” with guest editor V. Prasad Shastri 
(University of Freiburg, Germany), volume 2, issue 5, October 
2012.
The main objective of this themed issue on biomimetic and 
biofunctional materials in regenerative medicine is to highlight 
the evolution of concepts in materials engineering for inducing 
autologous regeneration and the challenges associated with 
clinical translation. In this context, material design that 
incorporates principles of directed self-assembly, surface 
engineering, metabolic engineering, extracellular matrix 
mimicry, and synthetic biology for driving functional cellular 
organization and for recapitulation of signaling environments 
in embryonic and fetal development are highlighted. 
“Nasal Drug Delivery,” with guest editors Elka Touitou 
(Hebrew University of Jerusalem, Israel) and Lisbeth Illum 
(Critical Pharmaceuticals, United Kingdom), volume 3, issue 1, 
February 2013.
The nasal route of administration for systemic action of drugs 
is an exciting growing field of research that opens avenues for 
investigation and design of new and more efficient products. 
This issue focuses on translational nasal drug delivery research. 
Reviews on the nasal administration route for systemic and 
nose-to-brain delivery cover absorption pathways, delivery 
systems, and devices. They are followed by papers on specific 
case studies on new carriers, drugs, and vaccines investigated in 
animals or administrated to humans. 
DDTR Update
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“Cancer Stem Cells,” with guest editor Jayanth Panyam 
(University of Minnesota, U.S.A.), volume 3, issue 2, April 2013.
There is growing evidence that cancers contain a small subset of 
stem-like cells called cancer stem cells (CSCs) that can self-
renew. CSCs may play a critical role in cancer treatment out-
comes because they are resistant to conventional chemotherapy 
and can initiate tumor recurrence following treatment. This 
theme issue reviews the role that CSCs may play in tumor 
response to therapy and strategies to inhibit CSCs. 
“Nano/Bio Interface: Impact on Drug Delivery Applications,” 
with guest editors Subhra Mohapatra, Srinivas Nagaraj, and 
Shyam S. Mohapatra (University of South Florida, U.S.A.), 
volume 3, issue 4, August 2013.
This special issue is partly based on the Collaborative 
International Conference 2012 (NBCIC 2012) that was 
organized by the University of South Florida Nanomedicine 
Research Center and was held March 22–24, 2012. NBCIC 
2012 brought together engineers, chemists, physicists, 
biologists, and clinicians from across the globe to discuss 
recent advances, opportunities, and barriers in nanoscience 
and nanotechnology and its applications to diagnosing and 
treating diseases.
“Nanomedicine: Prospects and Challenges,” with guest editors 
Padma V. Devarajan and Vandana B. Patravale (Institute of 
Chemical Technology, India), volume 3, issue 5, October 2013.
This special issue is a fallout of the Indo–U.S. joint symposium 
“Nanomedicine—Prospects and Challenges” organized at the 
Institute of Chemical Technology (Mumbai, India), jointly with 
Vinod Labhasetwar (Cleveland Clinic, U.S.A.) and supported 
by the Indo-US Science and Technology Forum. The issue is a 
blend of reviews and research manuscripts, covering diverse 
aspects of nanomedicine. 
“RNA Interference-Based Therapeutics and Diagnostics,” with 
guest editor Ken Howard (Aarhus University, Denmark) and 
Dan Peer (Tel-Aviv University, Israel), volume 4, issue 1, 
February 2014.
The capability to control and study cellular gene expression by 
the process of RNA interference (RNAi) has provided 
researchers with an unprecedented tool for investigating 
functional genomics and the potential to harness the RNAi 
mechanism as a potent therapeutic. The special issue covers the 
processes, molecules, and delivery solutions relevant for the 
clinical translation of RNAi.
“Proceedings of the Drug Delivery Australia 2012 
Symposium,” with guest editors Ben J. Boyd (Monash 
University, Australia) and Paul Young (University of Sydney, 
Australia), volume 4, issue 3, June 2014.
This issue is based on the 2012 Drug Delivery Australia 
conference, hosted by the Australian Local Chapter of the 
Controlled Release Society. In addition to research and review 
articles, the issue includes articles on clinical trials and clinical 
research. 
“Tissue Engineering,” with guest editors Sing Yian Chew 
(Nanyang Technological University, Singapore) and Kam 
Leong (Columbia University, U.S.A.), volume 5, issue 2, April 
2015.
The issue contains articles on nanofibers and their use for 
growth factor delivery, scaffolds and their interactions with 
cells, and hydrogels and other drug delivery systems for 
regenerative medicine. 
“Microneedles for Drug and Vaccine Delivery and Patient 
Monitoring,” with guest editors Ryan Donnelly (Queen’s 
University Belfast, Ireland) and Dennis Douroumis 
(University of Greenwich, United Kingdom), volume 5,
issue 4, August 2015.
In this issue, there is a focus on novel applications of 
microneedles in drug, vaccine, and gene delivery, as well as in 
minimally invasive monitoring and diagnosis. Topics include 
gene and drug delivery systems, vaccine delivery systems, and 
material design and production, with a strong focus on clinical 
translation and commercialization. 
DDTR Outstanding Research Paper Award
It is time to consider submitting your best research for the 2016 
DDTR Outstanding Research Paper Award. The paper will be 
selected from the research articles, clinical research, and clinical 
trials published in DDTR during 2016. The award will be 
presented during the 44th CRS Annual Meeting, to be held 
July 16–19, 2017, at Hynes Conventional Center, Boston, MA, 
U.S.A. Visit the CRS website for award criteria (www.
controlledreleasesociety.org/about/Awards/Pages/
DDTROustandingPaper.aspx). n
Most Downloaded DDTR Articles in 2015
Nasal Drug Delivery Devices: Characteristics and Performance 
in a Clinical Perspective—A Review
Per Gisle Djupesland
Drug Delivery Transl. Res. 3(1): 42-62 (2013)
Microneedle-Based Drug and Vaccine Delivery via Nanoporous 
Microneedle Arrays
Koen van der Maaden, Regina Luttge, Pieter Jan Vos, 
Joke Bouwstra, Gideon Kersten, and Ivo Ploemen
Drug Delivery Transl. Res. 5(4): 397-406 (2015)
A Paradigm Shift for Extracellular Vesicles as Small 
RNA Carriers: From Cellular Waste Elimination to Therapeutic 
Applications
Keitaro Hagiwara, Takahiro Ochiya, and Nobuyoshi 
Kosaka
Drug Delivery Transl. Res. 4(1): 31-37 (2014)
Vaginal Deployment and Tenofovir Delivery by 
Microbicide Gels
Y. Gao, A. Yuan, O. Chuchuen, A. Ham, K. H. Yang, and 
D. F. Katz
Drug Delivery Transl. Res. 5(3): 279-294 (2015)
Strategies for Intranasal Delivery of Vaccines
Mehfuz Zaman, Saranya Chandrudu, and Istvan Toth
Drug Delivery Transl. Res. 3(1): 100-109 (2013)
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Chapter News
The Malaysia Local Chapter of the Controlled Release Society (MyCRS) has successfully organised the first 
MyCRS Scientific Conference 2015 in conjunction with CRDDS2015. The event was held August 15–16 in 
Kuala Lumpur and coorganized with the Centre for Drug Delivery Research, Universiti Kebangsaan Malaysia. 
The conference attracted more than 50 participants from various countries including Taiwan, Thailand, India, 
and Iran. n
Controlled Release & Drug Delivery Symposium 2015
A group photo with all participants.
A postgraduate student in action during the student 3-minute 
pitching competition.
Judges in serious discussion during the poster presentation.
Networking during the conference dinner.
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Unorthodox Approach to Drug Delivery Research 
Lands Carnegie Mellon Professor on Popular Science’s 
2015 Brilliant 10 List
Business Wire: September 23, 2015 – PITTSBURGH, PA, 
U.S.A. – Kathryn Whitehead, an assistant professor of chemical 
engineering at Carnegie Mellon University, has been named by 
Popular Science as a 2015 Brilliant Ten winner for her innovative 
work on drug delivery systems.
Annually, Popular Science combs through hundreds of 
nominations from around the country to select the brightest 
minds in engineering and science. Whitehead earned the honor 
this year for designing nanoparticles that treat disease by 
delivering therapeutic drugs to specific areas in the body. Her 
research will revolutionize how we treat formidable diseases, 
such as cancer, diabetes, and hereditary disorders.
During her career, Whitehead has synthesized and tested nearly 
5,000 nanoparticle delivery vehicles en route to identifying a 
select few that potently shuttle drugs into exactly the right cells. 
This feat was challenging, in part, because the body’s immune 
system considers therapeutic nanoparticles to be foreign 
substances that need to be destroyed. However, Whitehead’s 
nanoparticles circumvent the immune system and are free to 
deliver medicine to cells in many parts of the body, including the 
liver, the skin, and the intestine. Whitehead’s research group is 
now using her nanoparticles to engineer therapies for maladies 
that include inflammatory bowel disease, chronic wounds, and 
non-Hodgkin’s lymphoma, a type of blood cancer.
“Cancer therapy is so difficult for patients, in large part, because 
of the toxic side effects of chemotherapy,” said Whitehead. “In 
contrast, our targeted nanoparticles deliver drugs only to 
cancerous tissue, sparing healthy cells. We expect these targeted 
treatments to extend the lives of cancer patients while increasing 
their quality of life through a reduction in side effects.”
Whitehead’s approach to finding the right nanoparticles for 
drug delivery was unorthodox in that it required her to examine 
a very large number of nanoparticles using high-throughput 
screening.
“Although high-throughput screening has not been a well-
accepted approach to scientific discovery, I felt strongly that we 
needed to test many compounds to maximize our chances of 
success,” said Whitehead. Her hard work has paid off in the 
discovery of these versatile nanoparticles, and she has broadened 
the scientific community’s understanding of how drug delivery 
chemistry affects efficacy. She is now able to predict which 
nanoparticles will work in living animals.
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“The Popular Science Brilliant 10 award acknowledges the power 
of Katie’s ideas and the important contributions that faculty 
members can make early in their careers,” says James H. Garrett, 
dean of the College of Engineering at Carnegie Mellon 
University.
“I’m here at Carnegie Mellon because I want to use my creativity 
and scientific skills for the betterment of society,” said Whitehead. 
“Knowing that our work could improve the lives of millions of 
patients is deeply satisfying.”
Past CRS President Tsuneji Nagai Received Honorary 
Doctorate
In early October, legendary professor and 
past CRS president Tsuneji Nagai 
received an honorary doctorate from 
Chulalongkorn University in Bangkok, 
Thailand. It was presented by Her Royal 
Highness Princess Maha Chakri 
Sirinthorn on behalf of the king and was 
the university’s first honorary degree 
presented in the pharmaceutical field.  
Prof. Nagai’s work in bioavailability studies and controlled drug 
delivery formulations has contributed greatly to the 
pharmaceutical science of Japan, Asia, and the world. His 
distinguished career includes leadership positions at Hoshi 
University, service on multiple boards, direction for the Nagai 
Foundation Tokyo, and a body of work that includes drug 
products, more than 60 patents, and more than 500 peer-
reviewed research papers. Prof. Nagai has immensely influenced 
students and colleagues, whose work continues to significantly 
impact delivery science. Through the Nagai Foundation Tokyo, 
he co-sponsors the annual CRS T. Nagai Postdoctoral Research 
Achievement Award. 
Past CRS President Robert Langer Presented with the 
Queen Elizabeth Prize for Engineering
On October 26, Robert Langer of the 
Massachusetts Institute of Technology 
was presented with the Queen Elizabeth 
Prize for Engineering, which includes a 
£1 million award. 
One of the highlights of the day was the 
Engineering Ambassadors’ reception at 
the Royal Academy of Engineering, 
featuring Langer’s address, “The 
Struggles and Dreams of a Young Engineer.” He recounted early 
People in the News continued on page 20
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career challenges in which he was refused research funding and 
continuously discouraged. His speech is available at http://
qeprize.org/createthefuture/trophy-presentation-2015.
Later in the day, guests gathered at Buckingham Palace to watch 
as Queen Elizabeth II presented the trophy, saying, “I am 
delighted to honour the achievements of Dr. Langer, whose 
pioneering research has brought enormous benefit to millions of 
people.”
Langer runs one of the largest academic laboratories in the world 
and is the most cited engineer in history (170,000 times). He has 
more than 800 patents granted or pending and has co-founded 
over 20 companies. His connections with CRS include belonging 
to the CRS College of Fellows, being a past president of CRS 
(1991–1992), and receiving the Founders Award (1989). Many 
prominent CRS members are connected in some way to the 
Langer Lab at MIT. Langer is known for bringing together 
researchers from many different disciplines, and this 
interdisciplinary approach is central to CRS and to our members’ 
work. n
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OUTSTANDING ACHIEVEMENT
DESERVES THE SPOTLIGHT
CRS award nominations 
accepted through 
January 15, 2016
Here’s your chance to 
recommend a colleague for 
a prestigious CRS award:
• College of Fellows
• Founders Award
• CRS T. Nagai Postdoctoral
 Research Achievement Award
• Young Investigator Award
The CRS website includes eligibility 
requirements, nomination process, 
and online nomination form at 
controlledreleasesociety.org/awards
A Valuable Resource—Oral Mucosal Drug Delivery and Therapy
The book Oral Mucosal Drug Delivery and Therapy, edited by Michael Rathbone, Sevda Senel, 
and Indiran Pather, examines the formulation challenges and clinical opportunities for delivering 
drugs locally and systemically to the oral cavity. The book contains 11 authoritative chapters that 
evaluate the major issues associated with the oral mucosa as a route for drug administration and 
provides solutions to overcome these challenges. There is a comprehensive description of how the 
anatomy and physiology of the oral cavity affects the design of oral mucosal drug delivery systems 
and provides a detailed description of current oral mucosal drug delivery technologies, including 
research, development, and assessment methods. Furthermore, solutions on how to improve drug 
permeability across, and increase retention time on, oral mucosa are also provided. The book also 
provides an insightful look into the future directions in research and product development of oral 
mucosal drug delivery systems. Oral Mucosal Drug Delivery and Therapy is a valuable resource for 
undergraduate and postgraduate students, academic staff, and researchers wanting to extend their 
knowledge in this field.
To order visit controlledreleasesociety.org/publications/Pages/CRSBooks.aspx. n
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October
Braeburn Pharmaceuticals Commends President Obama’s 
Commitment to Improving Treatment for Opioid 
Addiction
PRNewswire: October 22, 2015 – PRINCETON, NJ, U.S.A. – 
Braeburn Pharmaceuticals commends President Barack Obama 
for highlighting the importance of removing barriers to 
medication-assisted treatment (MAT) for people with opioid 
addiction. The president announced a series of initiatives among 
the public and private sectors and at all levels of government to 
address the opioid abuse epidemic. The president’s engagement 
amplifies the recent announcement by Department of Health 
and Human Services (HHS) Secretary Sylvia Burwell that HHS 
will revise federal regulations to expand access to MAT.
President Obama’s announcement focused on nationwide efforts 
to generate greater public awareness, educate opioid prescribers, 
and improve access to MAT for opioid use disorders. The Obama 
Administration has expanded insurance coverage of treatment 
for substance use disorders under the Affordable Care Act and 
has committed to improving access to FDA-approved 
medications containing buprenorphine for the treatment of 
opioid use disorders. 
“President Obama’s personal engagement is critical to raising 
awareness of the fact that opioid addiction is a problem for all of 
us and requires action from both the private and public sectors,” 
said Behshad Sheldon, president and CEO of Braeburn.
The Obama Administration has supported public-private 
cooperation to improve care for people with opioid use disorders 
since the president’s first year in office. In 2009, the National 
Institute on Drug Abuse (NIDA) provided a research grant to 
expedite the development of Probuphine®, an investigational, 
long-acting, implantable formulation of buprenorphine under 
development by Braeburn with Titan Pharmaceuticals, Inc. The 
Probuphine implant is intended to provide a consistent level of 
the medication for six months following a single treatment.
In addition to HHS and NIDA, the Food and Drug 
Administration (FDA) is also actively implementing the 
president’s plan to reduce opioid abuse and addiction, including 
issuance of guidance on abuse-deterrent formulations of opioids. 
FDA has provided Braeburn with guidance on the design of 
clinical trials of Probuphine and granted priority review for the 
Probuphine New Drug Application. FDA has designated 
February 27, 2016, as the target date for agency action.
“Our vision is for patients to have safe and effective long-acting, 
pill-free options that deliver precision medicine in neuroscience. 
In the News
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This means ensuring that patients get the right dose for an 
optimal duration. Probuphine is our foundational product, and 
we are dedicated to continuing research, development, and 
education in collaboration with both public and private partners 
active in treatment of opioid addiction and pain,” Sheldon said.
Currently available buprenorphine medications for opioid 
addiction are oral forms that require daily self-administration by 
patients. These traditional formulations are highly susceptible to 
risks of diversion, misuse, abuse, and accidental exposure given 
that patients must take responsibility for their postdispensing 
storage, proper use, and disposal.
If approved by FDA, Probuphine and other long-acting implants 
and injectables for addiction, pain, and other conditions could 
help reduce the problems that President Obama, Secretary 
Burwell, NIDA, FDA, and other stakeholders nationwide are 
working to address.
Probuphine is an investigational subdermal implant designed to 
deliver buprenorphine around the clock for six months following 
a single treatment and to promote patient compliance and 
retention. Buprenorphine, which is the active ingredient in 
multiple FDA-approved drug products for the treatment of 
opioid dependence, is currently available in tablet and film 
formulations that require self-administration by patients on a 
daily basis.
Probuphine was developed using ProNeura™, Titan 
Pharmaceuticals’ continuous drug delivery system that consists of 
a small, solid implant made from a mixture of ethylene-vinyl 
acetate (EVA) and a drug substance. The resulting construct is a 
solid matrix that is placed subdermally, normally in the upper 
arm, in an outpatient office procedure, and removed in a similar 
manner at the end of the treatment period.
The efficacy and safety of Probuphine has previously been 
studied in several clinical trials, including a 163-patient, placebo-
controlled study over a 24-week period (published in the Journal 
of the American Medical Association), and a follow-on study of 287 
patients (published in the journal Addiction).
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a 
pill-free pharmaceutical company delivering precision medicine 
in neuroscience. In September 2015 the Food and Drug 
Administration (FDA) accepted for review Braeburn’s New 
Drug Application for its lead candidate, Probuphine, a six-
month buprenorphine implant for treatment of opioid addiction. 
The agency set February 27, 2016, as the target date for action.
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Long-acting therapeutic treatment options can be essential to 
improving patient outcomes and facilitating recovery in these 
conditions, which are often complicated by stigma and present 
significant public health challenges. Braeburn’s investigational 
product pipeline consists of long-acting therapies for serious 
neurological and psychiatric disorders, including addiction, pain, 
and schizophrenia. Candidates include: Probuphine, a six-month 
buprenorphine implant for treatment of opioid addiction; 
CAM2038, weekly and monthly subcutaneous injection depot 
formulations of buprenorphine for treatment of opioid addiction 
and pain; a risperidone six-month implant for treatment of 
schizophrenia; and a novel molecule, ATI-9242, for treatment of 
schizophrenia. More information on Braeburn, an Apple Tree 
Partners company, can be found at www.
braeburnpharmaceuticals.com.
Ocular Therapeutix™ Announces Topline Results of Phase 
3 Clinical Trial for Dextenza™ for the Treatment of 
Allergic Conjunctivitis
Business Wire: October 22, 2015 – BEDFORD, MA, U.S.A. – 
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a 
biopharmaceutical company focused on the development and 
commercialization of innovative therapies for diseases and 
conditions of the eye, announced today topline efficacy results 
from a phase 3 clinical trial to evaluate the safety and efficacy of 
Dextenza™ (sustained release dexamethasone) 0.4 mg, 
intracanalicular depot for the treatment of allergic conjunctivitis. 
Dextenza is a product candidate administered by a physician as a 
bioresorbable intracanalicular depot and designed for extended 
drug release to the ocular surface for 30 days.
Treatment success was evaluated separately in this trial for ocular 
itching and conjunctival redness, and attainment of endpoints for 
both ocular itching and conjunctival redness has not been 
historically required by the U.S. Food and Drug Administration 
(FDA) for approval of drugs for allergic conjunctivitis.
The primary endpoint of treatment of ocular itching associated 
with allergic conjunctivitis was successfully achieved in this trial. 
There was a statistically significant difference (p < 0.0001) in the 
mean scores between the Dextenza treatment group and the 
placebo group for ocular itching at all three time points 
measured on day 7 postinsertion of the drug product. The 
difference in the scores for ocular itching between the Dextenza 
group and the placebo group was greater than 0.5 units at all 
time points on day 7 postinsertion and was greater than 1 unit at 
a majority of the time points on day 7 postinsertion.
The primary endpoint of conjunctival redness is typically an 
endpoint included in phase 3 trials for allergic conjunctivitis but 
has not been required for approval. The Dextenza treatment 
group did not achieve the primary endpoints for conjunctival 
redness in this trial. Many commercially available prescription 
medications for the treatment of allergic conjunctivitis have an 
ocular itching indication only. In this clinical trial, as well as 
other clinical trials completed to date, Dextenza has exhibited a 
strong safety profile and has been well tolerated.
“We are very pleased with the results of this phase 3 clinical trial 
in terms of the treatment of ocular itching associated with 
allergic conjunctivitis,” stated Amar Sawhney, Ph.D., chairman, 
chief executive officer, and president. “We believe that the design 
modifications made from our phase 2 program contributed to 
the successful achievement of the primary endpoint for ocular 
itching. Based on the results from this trial, we expect to advance 
this program into a second phase 3 clinical trial in allergic 
conjunctivitis before the end of 2015. We believe the results from 
this trial, as well as data from the previous phase 2 study, provide 
evidence supporting the safety and efficacy of our sustained 
release drug delivery platform that we continue to leverage across 
multiple ocular diseases and conditions.”
Michael B. Raizman, M.D., Ophthalmic Consultants of Boston, 
New England Eye Center, Tufts University School of Medicine, 
stated, “The clinical data for Dextenza indicate that this 
promising product candidate has potential to serve as an effective 
alternative to self-administered drops for patients experiencing 
itching associated with allergic conjunctivitis. Dextenza offers 
one-time seasonal administration in a preservative-free product, 
is designed to avoid the peaks and valleys associated with topical 
dosing, and has the potential to minimize or eliminate the side 
effects associated with eye drops. The results for ocular itching 
are encouraging given that I consider itching to be the most 
relevant endpoint for my patients.”
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a 
biopharmaceutical company focused on the development and 
commercialization of innovative therapies for diseases and 
conditions of the eye using its proprietary hydrogel platform 
technology. Ocular Therapeutix’s lead product candidates are in 
phase 3 clinical development for postsurgical ocular 
inflammation and pain and allergic conjunctivitis, and phase 2 
clinical development for glaucoma and inflammatory dry eye 
disease. The company is also evaluating sustained-release 
injectable anti-VEGF drug depots for back-of-the-eye diseases. 
Ocular Therapeutix’s first product, ReSure® sealant, is FDA-
approved to seal corneal incisions following cataract surgery.
Impax Receives FDA Approval for Generic Version of 
Intuniv® (Guanfacine) Extended-Release Tablets, 1, 2, 3, 
and 4 mg
PRNewswire: October 21, 2015 – HAYWARD, CA, U.S.A. – 
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced 
that the U.S. Food and Drug Administration (FDA) has 
approved its generic version of guanfacine extended-release 
tablets 1, 2, 3, and 4 mg.
Fred Wilkinson, president and chief executive officer of Impax, 
stated, “Since the resolution of the warning letter at the Hayward 
facility in early September, the FDA has approved three generic 
products from this facility in the last five weeks. Generic 
guanfacine was one of the products waiting for the resolution of 
the warning letter, and we did not include it in the 14 potential 
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generic product launches for 2015. We are now evaluating the 
viability of this very competitive multi-player market and 
potential commercialization of this product. Additionally, we will 
continue to work with the FDA toward approval of our pending 
Abbreviated New Drug Applications at our Hayward facility.”
According to IMS Health (NSP), U.S. brand and generic sales 
of guanfacine extended-release tablets 1, 2, 3, and 4 mg were 
approximately $689 million for the 12 months ending in August 
2015.
Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical 
company applying its formulation expertise and drug delivery 
technology to the development of controlled-release and 
specialty generics in addition to the development of central 
nervous system disorder branded products. Impax markets its 
generic products through its Impax Generics division and 
markets its branded products through its Impax Specialty 
Pharma division. Additionally, where strategically appropriate, 
Impax develops marketing partnerships to fully leverage its 
technology platforms and pursues partnership opportunities that 
offer alternative dosage form technologies, such as injectables, 
nasal sprays, inhalers, patches, creams, and ointments. For more 
information, please visit the company’s website at www.
impaxlabs.com.
Flowonix Medical Inc. and Cerebral Therapeutics, LLC, 
Announce Exclusive Agreement for Drug Delivery to 
Brain
PRNewswire: October 21, 2015 – MOUNT OLIVE, NJ, 
U.S.A. – Flowonix Medical Inc. of New Jersey and Colorado-
based Cerebral Therapeutics, LLC, announced today that they 
have entered into an exclusive agreement to develop a unique 
implanted drug delivery system that provides direct infusion 
of a therapeutic drug into targeted areas of the brain for 
treatment of neurological diseases. By delivering microdoses 
of medication directly to the brain, this system will be able to 
bypass the blood-brain barrier and deliver the medication to a 
specific targeted region.
“Neurological disorders can be devastating to patients and their 
families, and patients are often left with few options,” stated 
Steven Adler, president and CEO of Flowonix Medical Inc. 
“Flowonix has long been a world leader in implantable infusion 
systems, and we have specific expertise in the accurate and 
reliable delivery of microdoses of medication. We are pleased to 
partner with Cerebral Therapeutics to bring this safe, effective, 
and successful drug delivery technology to one of the most 
challenging frontiers in medicine—the brain.”
“The combination of small-molecule therapy with established 
infusion pump delivery could be a treatment alternative with 
profoundly positive ramifications,” stated Dr. Ashwini Sharan, 
neurosurgical and neurological professor at Jefferson University 
and president-elect for the North American Neuromodulation 
Society (NANS). “The use of implantable infusion pumps to 
deliver novel therapeutic agents holds great promise.”
“Cerebral Therapeutics chose to work with Flowonix because the 
Prometra® and Prometra® II infusion pumps offer a patented 
valve-gated drug delivery system that allows for very precise 
dosing of medicine,” stated Dr. Dan Abrams, CEO of Cerebral 
Therapeutics. “The state-of-the-art Prometra pump platform will 
be used to deliver medication directly to the brain. For certain 
agents, this may reduce the doses necessary for therapeutic effect, 
lessen the risk of systemic toxicity, and possibly ameliorate the 
side effects associated with certain types of neurological 
therapies.”
The new agreement will allow Cerebral Therapeutics, LLC, and 
Flowonix Medical Inc. to develop drug-pump combination 
products aimed at addressing unmet needs in neurological 
therapies.
“Clinical trials will be needed to ascertain how targeted delivery 
of drugs directly to the brain may benefit neurological patients,” 
continued Dr. Dan Abrams. “Experience with intraspinal drug 
therapy demonstrates the many advantages of controlled and 
targeted drug therapy. We look forward to working with 
Flowonix because of their state of the art technology, 
commitment to developing new therapies, and leadership in 
infusion pump devices.”
Steve Adler continued, “This is an important partnership for 
Flowonix, which already has the privilege of being a leader in 
bringing infusion pump technology to address the largely unmet 
need of chronic pain. It demonstrates our commitment at 
Flowonix to bringing the most advanced technology to our 
physicians when treating their most challenging patients, 
particularly those with neurological conditions and with few 
other treatment options.”
Flowonix Medical Inc. (www.flowonix.com) headquartered in 
Mt. Olive, New Jersey, is dedicated to working with healthcare 
professionals to help ease suffering associated with chronic pain 
and allow patients to reclaim their lives through innovation and 
therapy advancements. The strategic business goal of Flowonix 
Medical Inc. is to become the leading implantable drug delivery 
company in the world. Founded in 2005, Flowonix Medical Inc. 
received approval to conduct its first clinical trial in 2007 on the 
Prometra programmable implantable pump. The company 
received approval by the FDA to market the Prometra in 2012. 
Flowonix Medical Inc. has been granted multiple patents and is 
focused on working closely with physicians to rapidly improve 
the capabilities of implantable drug delivery and management 
systems. For more information, please visit www.flowonix.com. 
Cerebral Therapeutics, LLC (www.cerebraltherapeutics.com) is a 
privately held company founded with the goal of addressing the 
well-recognized limitations of existing treatments for 
uncontrolled neurological diseases. Cerebral Therapeutics is 
combining advanced micro-dosing technology with proprietary 
medications to precisely deliver treatments to the other side of 
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the blood-brain barrier to improve the lives of patients with 
uncontrolled neurological disease. With a promising route of 
administration, Cerebral Therapeutics offers a new approach to 
managing neurological diseases by means of delivering ideal 
dosing to targeted sites within the brain. Initially, Cerebral 
Therapeutics is focused on improving outcomes for patients with 
refractory epilepsy by targeting the site of the seizure generation 
and propagation in the brain. Future cerebral therapeutic areas 
include obesity, Alzheimer’s disease, Parkinson’s disease, anxiety 
spectrum disorder, and brain cancer.
Portal Instruments Closes a $25 Million Series B Financing 
to Commercialize Its Transformative Needle-Free Drug 
Delivery System
PRNewswire: October 20, 2015 – CAMBRIDGE, MA, 
U.S.A. – Portal Instruments, Inc., a clinical stage drug delivery 
device company, announced today that it has closed a financing 
for $25 million of its series B preferred stock led by 5AM 
Ventures and joined by Portal’s existing private and strategic 
investors, including Sanofi Sunrise. The company has received an 
initial investment of $10 million, with an additional $15 million 
due upon the achievement of certain milestones. 
Proceeds from the series B financing will be used to further 
develop Portal’s groundbreaking computerized needle-free drug 
delivery system for injectable biologics for chronic diseases and 
to advance commercialization of its first product. The underlying 
technology is supported by a unique intellectual property 
portfolio of more than 50 patents conceived and prototyped at 
Massachusetts Institute of Technology (MIT) by world 
renowned inventor, scientist, and entrepreneur Ian Hunter, 
Ph.D., Hatsopoulos Professor of Mechanical Engineering and 
head of the Bio Instrumentation Laboratory at MIT, a founder 
of the company, and to which Portal Instruments has a 
worldwide exclusive license.
“Portal Instruments is transforming the patient experience for 
the delivery of injectable biologics for chronic diseases,” said 
Patrick Anquetil, CEO. “Administering high viscosity, high 
concentration biologics is a challenge for the biopharma industry 
as the drugs have to be needle-injected subcutaneously, which is 
a slow and painful experience for patients. Drug adherence is a 
huge problem in chronic diseases, and needle-related safety 
concerns are real. The Portal device offers a transformed patient 
experience. The injection is needle-free, fast, with shorter 
injection duration and sensation for the patient. The device is 
easy to use, and digital health features empower the patient to 
holistically manage their chronic condition and improve their 
adherence. We are excited to have a respected life sciences 
venture capital firm such as 5AM Ventures join us on our 
mission.”
Jim W. Young, Ph.D., venture partner at 5AM Venture 
Management, said, “Portal’s breakthrough drug delivery system 
has the potential to address the administration of high 
concentration, viscous biologics in a safe, accurate manner that 
can significantly improve the patient experience.” Young 
continued, “Portal has an extensive intellectual property portfolio, 
a first-class team of scientists and engineers, and a management 
team with a strong track record in the biotech industry. We are 
excited to be part of the company.”
Portal Instruments is developing a unique platform technology 
to transform the delivery of modern medicines and improve the 
patient experience. Portal’s patented technology enables the 
precise delivery of the exact amount of drug at the desired tissue 
depth irrespective of drug viscosity and composition, particularly 
important for today’s new biological drugs. The company’s 
injection mechanism delivers the injection with minimal 
sensation and is highly customizable across a large variety of 
medical, animal, agricultural, and cosmetic applications.
Portal Instruments seeks to partner with biopharmaceutical 
companies to enable greater differentiation and penetration of 
their individual billion dollar biologic franchises. Portal is backed 
by venture investors and strategic partners, including 5AM 
Ventures and Sanofi Sunrise, and seeks additional 
biopharmaceutical partners to collaborate on specific drug-device 
combination products that can drive new market growth, 
improve differentiation, and help with patient adherence. For 
more information, please visit www.portalinstruments.com or 
follow @portalcambridge on Twitter.
Enteris BioPharma’s Formulation Technology Enables 
Oral Delivery of Tarsa Therapeutics’ TBRIA™ 
PRNewswire: October 19, 2015 – BOONTON, NJ, U.S.A. – 
Enteris BioPharma, Inc., an industry leader in oral peptide 
delivery, congratulates Tarsa Therapeutics on the submission of a 
New Drug Application (NDA) to the U.S. Food and Drug 
Administration (FDA) for TBRIA™ (calcitonin-salmon [rDNA 
origin] delayed release tablets) in July 2015, which has now been 
accepted for review by the FDA with a user fee goal date of May 
30, 2016. TBRIA is a once-daily oral recombinant salmon 
calcitonin tablet for the treatment of postmenopausal 
osteoporosis in women greater than 5 years postmenopause when 
alternative treatments are not suitable (e.g., patients for whom 
other therapies are contraindicated or for patients who are 
intolerant or unwilling to use other therapies).
Tarsa’s formulation of TBRIA uses proprietary, patented oral 
delivery technology licensed from Enteris BioPharma. Tarsa has 
exclusive development and worldwide commercialization rights 
to the oral calcitonin product developed with Enteris’ technology, 
with the current exception of China.
Enteris BioPharma, Inc., is a privately held, New Jersey–based 
biotechnology company offering innovative formulation 
solutions built around its proprietary drug delivery technologies. 
Enteris’ proprietary oral delivery technology has been the subject 
of numerous feasibility studies and active development programs, 
several of which are in late stage clinical development. For more 
information on Enteris BioPharma and its proprietary oral 
delivery technology, please visit www.EnterisBioPharma.com.
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Positive Four-Year Clinical Data from Micell Technologies’ 
MiStent SES Presented at TCT 2015
PRNewswire: October 13, 2015 – DURHAM, NC, U.S.A. – 
Micell Technologies, Inc., today announced four-year clinical 
results from the DESSOLVE I and II trials of its MiStent 
sirolimus-eluting absorbable polymer coronary stent system 
(MiStent SES®) were presented at the 27th Annual 
Transcatheter Cardiovascular Therapeutics (TCT) Conference 
held in San Francisco, October 11–15. TCT is the world’s largest 
educational meeting specializing in interventional cardiovascular 
medicine. MiStent SES was designed to optimize vessel healing 
in patients with coronary artery disease, and data presented at 
TCT demonstrated both sustained and desirable long-term 
clinical and safety outcomes.
An oral presentation titled “Device and Clinical Program 
Highlights: Micell” was delivered by Alexandra Lansky, M.D., 
director of interventional cardiovascular research, Yale University 
School of Medicine, New Haven, Connecticut. Highlights of the 
data included no target lesion events in the DESSOLVE I study 
and sustained clinical outcomes in both DESSOLVE I and II 
through four years’ follow-up. There have been no probable or 
definite stent thromboses in either study. Importantly, the 
MiStent SES continues to show a low combined target lesion 
revascularization (TLR) rate for DESSOLVE I and II of 2.7% 
at 4 years’ follow-up, which is consistent with previously 
demonstrated lack of late loss progression in the DESSOLVE I 
study.
Dr. Lansky commented, “A key advantage that appears to be 
conferred by MiStent SES is sustained local drug delivery 
beyond the presence of the polymer. That’s exciting to me as a 
clinician because it means MiStent may provide therapeutic 
sirolimus levels in the tissue around the stent for up to nine 
months, while limiting the duration of that patient’s exposure to 
polymer. Currently, there is no approved drug-eluting stent that 
provides full elimination of the polymer by three months without 
concomitant loss of anti-restenotic drug effects.”
Dennis Donohoe, M.D., Micell’s chief medical advisor, added, 
“DESSOLVE data, now reported out to four years’ follow-up, 
has been remarkably consistent in demonstrating that the unique 
bioabsorbable drug-eluting stent design of MiStent SES 
provides clinically meaningful results without probable or 
definite stent thromboses related to its use.”
MiStent SES® is designed to optimize healing in patients with 
coronary artery disease. The rapidly absorbable coating of 
MiStent SES, which contains crystalline drug (sirolimus) and an 
absorbable polymer, is intended to precisely and consistently 
provide for local drug delivery and limit the duration of polymer 
exposure. These characteristics potentially reduce the safety risks 
associated with currently commercially available drug-eluting 
stents.
Using an approved drug (sirolimus) and polymer (PLGA), 
Micell’s patented supercritical fluid technology allows a 
rigorously controlled drug/polymer coating to be applied to a 
bare-metal stent. MiStent SES leverages the benefits of a cobalt 
chromium coronary stent system—a state-of-the-art, thin-strut, 
bare-metal stent that has demonstrated excellent deliverability, 
conformability, and flexibility.
The European Union’s approval of MiStent SES was supported 
by clinical data from two studies, DESSOLVE I and II. 
DESSOLVE II demonstrated superior in-stent late lumen loss 
rates and an excellent safety profile. In 2015, clinical sites in 
Europe and China began enrolling patients in DESSOLVE III 
and DESSOLVE C, respectively. DESSOLVE III is a 
prospective, randomized, balanced, controlled, single-blind, 
multi-center study comparing clinical outcomes between 
MiStent SES and Xience in a “real world, all-comers” patient 
population. DESSOLVE C is a prospective, randomized, 
controlled, single-blind, multi-center clinical trial to demonstrate 
MiStent SES’s efficacy and safety. DESSOLVE C, intended to 
support regulatory approval of MiStent SES in China, is being 
sponsored by Hefei Life Science Technology Park Investment 
and Development Co., Ltd., in conjunction with Micell. MiStent 
SES is not approved by the Food and Drug Administration for 
sale or use in the United States.
SynAgile Corporation Announces Positive Phase 2a 
Results for Continuous, Noninvasive, Intraoral Levodopa-
Carbidopa Administration to Treat Parkinson’s Disease
PRNewswire: October 8, 2015 – WILSON, WY, U.S.A. – 
SynAgile Corporation (www.SynAgile.com), a privately held 
pharmaceutical company that develops and commercializes drug 
delivery systems using its proprietary OraFuse™ intraoral 
technology platform, today announced positive results from a 
proof-of-concept, phase 2a, open-label clinical trial of 
continuous intraoral administration of levodopa-carbidopa 
(LD/CD).
“We are extremely pleased that the primary and secondary 
endpoints in our phase 2a trial were met, demonstrating that 
continuous intraoral delivery of LD/CD provides reduced 
variability in plasma levodopa concentrations and a significant 
reduction in motor complications. OFF time was reduced by 
43% compared with standard oral LD/CD tablet therapy,” said 
Ephraim Heller, CEO of SynAgile. “SynAgile is developing its 
DopaFuse™ product as a continuous, noninvasive LD/CD 
therapy to address the problem of levodopa-induced motor 
complications, a large, unmet need facing Parkinson’s patients 
today. These results were achieved with a noninvasive therapy 
that requires no surgery, bulky pumps, or needles. Continuous 
intraoral LD/CD therapy will appeal to many patients whose 
motor complications are not adequately controlled with standard 
oral medications. Furthermore, DopaFuse™ will potentially 
avoid the side effects and human factor problems associated with 
deep brain stimulation and Duodopa™ therapy.”
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Motor complications include OFF time and dyskinesia 
associated with chronic levodopa treatment. Motor 
complications affect most patients with advanced Parkinson’s 
disease and are considered to be one of the most important 
issues facing Parkinson’s disease patients today.
“Motor complications, and specifically OFF time, can have a 
profoundly negative impact on the lives of Parkinson’s disease 
patients. A safe, convenient, noninvasive, nonsurgical, oral 
levodopa therapy would be a major advance in treatment,” said 
Prof. Warren Olanow, co-principal investigator of the study, 
chairman emeritus, Department of Neurology, Mount Sinai 
School of Medicine, CEO of Clintrex LLC, and a member of 
the SynAgile Scientific Advisory Board. “The reduction in OFF 
time was clinically significant, and there were no treatment-
related adverse events. The results suggest that continuous 
intraoral LD/CD administration may provide a safe, noninvasive 
approach for controlling OFF time,” said Prof. Olanow.
The study compared continuous intraoral administration of LD/
CD versus standard intermittent LD/CD tablets taken 4–8 times 
daily in patients with advanced Parkinson’s disease. Continuous 
administration was defined as administration of a dose of LD/
CD suspension every 5–10 minutes. Each patient served as his/
her own control (described below). For the primary endpoint, 
statistically significant improvements were observed for variability 
in plasma levodopa concentration (as determined by linearity) 
and for reduction in 1-hour and 2-hour fluctuation indexes (p < 
0.001 for each). OFF time was reduced by 43% (p < 0.001), and 
the UPDRS Part III motor score improved (p = 0.010).
The phase 2a trial was an open-label, single-center study of 18 
Parkinson’s disease patients who experienced ≥2 hours of OFF 
time per day. Profs. Warren Olanow and Fabrizzio Stocchi 
served as co-principal investigators. Standard intermittent oral 
LC/CD tablets were compared with the same total doses of LD/
CD suspension delivered into the mouth every 5–10 minutes. 
The study was conducted at Hospital San Raffaele in Rome, 
Italy. Patients were admitted to the clinic on day 1 for baseline 
evaluations. On day 2 (the “control day”), LD/CD was 
administered as commercially available LD/CD tablets at each 
patient’s pre-baseline dosing regimen. Plasma levels of levodopa 
as well as ON and OFF time were measured repeatedly over the 
course of 8 hours. On day 3 (the “PK day”), a suspension of LD/
CD was administered intraorally every 5–10 minutes over a 
period of 8 hours at a dose equal to the total dose of standard 
oral LD/CD that the patient consumed over the same 8-hour 
period on the control day, and plasma levels of levodopa were 
obtained. On day 4 (the “efficacy day”), each patient received his 
or her first LD/CD morning dose as an oral tablet at the same 
dosage as the first morning dose on the control day. They then 
received the balance of the total 8-hour dose that they took on 
the control day by way of intraoral administration of a 
suspension of LD/CD every 5–10 minutes over a period of 8 
hours. ON and OFF time were assessed as on day 2. Patients 
were then discharged from the clinic on their standard 
medication and returned on day 18 for a safety evaluation.
The primary endpoint was defined as the variability of the 
levodopa concentrations; we compared standard intermittent oral 
and continuous intraoral administration. Pharmacokinetic 
endpoints included deviation from linearity and the mean 
levodopa fluctuation index (Cmax−Cmin)/Caverage). Efficacy 
was measured by neurologist-based assessment of motor state 
and dyskinesia at 30-minute intervals over the 8 hours and by 
UPDRS Part III, assessed at 0, 2, 4, and 8 hours on the control 
day (day 2) and the efficacy day (day 4).
Safety parameters measured included physical examinations, 
neurological examinations, ECGs, vital signs, blood and urine 
laboratory assessments, and oral site assessments by both the 
neurologist and the patient. Full results of the study will be 
presented at an upcoming scientific meeting.
SynAgile is developing the OraFuse™ drug delivery platform for 
the continuous oral delivery of drugs with poor 
pharmacokinetics. OraFuse™ consists of a miniature, disposable, 
drug-delivery device carried on a small, tooth-attached retainer 
that continuously infuses medication into the mouth. SynAgile’s 
first product is DopaFuse™, which uses the OraFuse™ device to 
infuse a proprietary formulation of LD/CD into the mouth for 
the treatment of Parkinson’s disease. DopaFuse™ is being 
developed for daily use by Parkinson’s disease patients. The LD/
CD is swallowed with the patient’s saliva and absorbed via the 
conventional gastrointestinal route. The DopaFuse™ drug 
formulation has no taste, and the infusion is imperceptible to the 
patient. The DopaFuse™ system is not visible to others, is 
comfortable to wear, and does not interfere with speech, 
swallowing, or drinking. DopaFuse™ is intended to enable 
patients with Parkinson’s disease to achieve more-constant 
plasma levodopa levels and reduce their motor complications. 
DopaFuse™ will provide patients with a safe, convenient, 
noninvasive therapy to reduce motor complications. In contrast 
to other continuous levodopa delivery systems, DopaFuse™ 
requires no surgical procedures or needles.
Levodopa is widely recognized as the most efficacious treatment 
for Parkinson’s disease symptoms. However, levodopa is quickly 
broken down in the body, and its absorption is unpredictable. 
Even when taken 4–8 times per day, standard oral levodopa 
tablets often produce widely varying plasma levodopa 
concentrations over the course of the day. Low plasma levodopa 
concentrations typically result in OFF time, characterized by 
tremor, rigidity, slowness of movement, and postural instability. 
High plasma levodopa concentrations often result in dyskinesia, 
characterized by involuntary muscle movements. Patients with 
advanced Parkinson’s disease can spend many hours each day in 
the OFF state or with dyskinesia.
Over one million people in the United States and over seven 
million people worldwide suffer from Parkinson’s disease, a 
neurodegenerative disorder caused by the diminished production 
of dopamine, which results in progressive impairment of motor 
function, including tremors at rest, rigidity, and impaired 
movement. Even when treated with the current standard of care, 
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the majority of patients with advanced Parkinson’s disease 
continue to experience motor complications (OFF periods and 
dyskinesia). These motor complications reduce patients’ ability to 
lead productive, independent lives and are recognized by patients, 
caregivers, and healthcare professionals as one of the most 
troubling and debilitating issues associated with the disease.
SynAgile is a biopharmaceutical company focused on developing 
and commercializing transformative therapeutics using its 
proprietary OraFuse™ intraoral continuous dosing technology, 
with an initial focus on treating debilitating motor complications 
in patients with Parkinson’s disease using its DopaFuse™ 
levodopa-carbidopa therapy. OraFuse and DopaFuse are 
trademarks of SynAgile Corporation. Duodopa is a trademark of 
AbbVie Inc.
Perrigo and Flamel Enter Into Exclusive Licensing 
Agreement for LiquiTime® Extended Release Suspension 
Technology in the U.S. OTC Market
PRNewswire: October 5, 2015 – DUBLIN, Ireland – Perrigo 
Company plc (NYSE: PRGO; TASE) and Flamel Technologies 
(NASDAQ: FLML) announced today that they have entered 
into an exclusive licensing agreement for LiquiTime® extended 
release suspension. The technology will be utilized in the 
development of a portfolio of extended release suspension 
products intended for the U.S. OTC marketplace. 
Michael Anderson, CEO of Flamel, said, “We are very pleased 
to partner with Perrigo on our LiquiTime® technology and look 
forward to continued successful development programs and 
commercial launches with Perrigo.” 
Perrigo’s chairman and CEO Joseph C. Papa stated, “This 
partnership with Flamel on their innovative LiquiTime® 
technology demonstrates our continued focus on the ‘Base Plus 
Plus Plus’ strategy. This is yet another excellent example of 
Perrigo’s commitment to providing Quality Affordable 
Healthcare Products® for our customers across the globe.” 
Impax Receives FDA Approval for Generic Version of 
Diabeta® (Glyburide) Tablets, USP, 1.25, 2.5, and 5 mg
PRNewswire: October 5, 2015 – HAYWARD, CA, U.S.A. – 
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced 
that the U.S. Food and Drug Administration (FDA) has 
approved its generic version of glyburide tablets 1.25, 2.5, and 5 
mg. The company is preparing for commercialization of this 
product through Impax’s generic division.
“We are pleased to receive approval of generic glyburide tablets, a 
product that was developed at our Middlesex, New Jersey, 
facility,” said Fred Wilkinson, president and chief executive 
officer of Impax. “Our diversified internal and external R&D 
network has delivered seven generic product approvals this year. 
With a pending Abbreviated New Drug Application pipeline of 
30 products, we have multiple opportunities to further expand 
our commercialized portfolio.”
According to IMS Health (NSP), U.S. brand and generic sales of 
glyburide tablets 1.25, 2.5, and 5 mg products were 
approximately $14 million for the 12 months ending in August 
2015.
Genisphere Closes $4 Million for Expansion of 3DNA® 
Targeted Drug Delivery Platform
PRNewswire: October 1, 2015 – HATFIELD, PA, U.S.A. – 
Genisphere LLC, provider of the 3DNA® nanotechnology 
platform, announced it has closed a $4 million equity round. This 
round of fundraising will extend and expand development of 
Genisphere’s targeted drug delivery platform, with the goal to 
license the 3DNA® platform to pharmaceutical partners and 
complete the preclinical work necessary to advance the 
company’s lead drug candidates.
One of the significant investors is Main Line Health’s Lankenau 
Institute for Medical Research (LIMR), a nonprofit biomedical 
research center committed to investing in promising and 
innovative research that will advance medical breakthroughs, 
improve patient care, and contribute to positive outcomes. 
George Prendergast, LIMR president and CEO, said, “We are 
looking forward to collaborating with Genisphere to fulfill our 
mission of translating our promising research into practical 
application at the bedside.”
Previously, Genisphere established several programs and key 
collaborations to generate preclinical data showing the versatility 
and efficacy of the 3DNA® platform in targeted delivery of small 
molecules, biologics, and nucleic acids. Bob Getts, chief science 
officer at Genisphere, said, “The results from each of our studies 
support the value of targeting and the versatility of the platform 
to cross biological barriers, like the blood brain barrier, to deliver 
therapeutic candidates. Our efficacy data continues to 
demonstrate that we can impact tumor growth and increase the 
life span in our treatment groups using a variety of therapeutic 
candidates, including small drugs and siRNAs.” According to 
Getts, the recent funds will be used to support focused 
preclinical projects designed to mature one of the company’s 
therapeutic leads with an eye on the clinic and getting first in 
human data.
Genisphere’s newly appointed CEO, Tom Bliss, pointed out 
while research has shown DNA to be a nontoxic, biocompatible 
drug delivery material, Genisphere is the only commercial source 
of DNA-based nanocarriers. He summarized, “The company has 
built a strong portfolio in the area of drug delivery. We are 
uniquely positioned to continue to support our pharmaceutical 
partners and complete the GLP work necessary for an IND 
filing.” 
Genisphere LLC is the provider of the 3DNA® platform for tar-
geted drug delivery. 3DNA® is a nanoscale, multivalent scaffold 
made from proprietary, synthetic DNA formed in a flexible, 
branched structure. 3DNA® nanocarriers are engineered and 
AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE
In the News continued on page 28
28
cross-linked to form a stable architecture while maintaining
 the biocompatibility of the nucleic-acid building blocks, and 
demonstrate efficacy and safety with a variety of drug cargos 
across multiple indications. Genisphere’s technology is IP-pro-
tected and fully customizable to deliver small molecules, biolog-
ics, and nucleic acids with precise specificity enabled by multiva-
lent targeting via antibodies, peptides, and other molecular enti-
ties. Genisphere leverages a collaborative model to advance its 
3DNA® drug delivery platform, and seeks additional partnerships 
with biotechnology and pharmaceutical companies to improve 
efficacy and reduce toxicity. Genisphere is also advancing its own 
lead compounds based on 3DNA® nanotechnology. For more 
information, please visit http://genisphere.com.
Tris Pharma Launches Generic Tussionex® as Par’s Rights 
Expire
PRNewswire: October 1, 2015 – MONMOUTH JUNCTION, 
NJ, U.S.A. – Tris Pharma, a specialty pharmaceutical company 
that develops innovative drug delivery technologies, announced 
the launch of Tris-labeled generic Tussionex®, an extended-
release suspension containing hydrocodone polistirex and 
chlorpheniramine polistirex.
Tussionex®, originally approved in the early 1980s, had no
 generic competition until 2010 when Tris Pharma’s generic 
product entered the market under an exclusive distribution 
agreement with Par Pharmaceuticals. Under the terms of the 
distribution agreement, Par had the exclusive right to market 
Tris Pharma’s hydrocodone polistirex and chlorpheniramine 
polistirex ER oral suspension for a five year period ending Sep-
tember 30, 2015. With the conclusion of the five year term, the 
rights have reverted back to Tris and as of October 1, 2015, hy-
drocodone polistirex and chlorpheniramine polistirex ER sus-
pension in 115 and 473 mL bottles (compare to Tussionex®) will 
be marketed and distributed by Tris Pharma’s generic business.
Unlike the original product based on 1970s technology 
involving organic solvent based coating, Tris’s product is based 
on its patented and highly versatile technology, LiquiXR®, which 
avoids the use of toxic organic solvents by employing an aqueous 
based coating system. Tris has pioneered the delivery of taste-
neutral, extended release dosage forms such as liquids, ODT/
chewable tablets, and film strips that are otherwise traditionally 
associated with immediate release.
Manufactured at Tris’s U.S. Food and Drug Administration 
(FDA)-inspected, state-of-the-art facility in Monmouth 
Junction, New Jersey, hydrocodone polistirex and 
chlorpheniramine polistirex 10 mg/8 mg ER suspension in 115 
and 473 mL bottles (compare to Tussionex®) are now available 
in the United States through wholesalers and distributors, as 
well as directly to the trade. Hydrocodone polistirex and 
chlorpheniramine polistirex 10 mg/8 mg ER suspension was 
approved by the FDA on October 1, 2010. It is distributed in 
accordance with FDA and U.S. Drug Enforcement 
Administration (DEA) regulations governing the handling of 
CII controlled substances.
September
ViaCyte Announces the Publication of a Report on 
Macroencapsulated Stem Cell-Derived Insulin-Producing 
Cells and the Issuance of Three Patents
PRNewswire: September 10, 2015 – SAN DIEGO, CA, 
U.S.A. – ViaCyte, Inc., a privately held regenerative medicine 
company with the first stem cell-derived islet replacement therapy 
for the treatment of diabetes in clinical trials, today announced 
publication of a study demonstrating that insulin-producing cells 
created in vitro from human embryonic stem cells can mature and 
function after being encapsulated and implanted into an animal 
model. In addition, the company announced the addition of three 
patents to its extensive portfolio covering its cell therapy platform. 
The article, entitled “Insulin-Producing Endocrine Cells 
Differentiated In Vitro from Human Embryonic Stem Cells 
Function in Macroencapsulation Devices In Vivo,” is published in 
Stem Cells Translational Medicine (October 2015 issue; e-published 
online August 24, 2015). In the June 2015 issue of the same 
journal, ViaCyte scientists published a review article summarizing 
the advances in bioprocessing and scale-up that have enabled 
ViaCyte’s VC-01™ product candidate to be the first stem cell–
based treatment for type 1 diabetes to enter clinical testing. 
The current article describes beta-like cells that have similar 
properties to the pluripotent stem cell-derived insulin-producing 
cells reported by other groups, except that ViaCyte produced 
populations with substantially higher endocrine cell content. The 
results demonstrated for the first time that nearly pure in vitro-
produced endocrine cells can function in vivo. Populations 
comprised of up to 98% endocrine cells (and less than 2% 
pancreatic progenitor cells) exhibited robust glucose-responsive 
insulin production in a mouse model. 
The cells in the study were differentiated further down the beta 
cell lineage than the PEC-01™ pancreatic progenitor cells being 
tested in ViaCyte’s VC-01 product candidate, which is currently 
in a phase 1/2 clinical trial for treatment of type 1 diabetes. The 
animal study also demonstrated for the first time that when 
encapsulated in a device and implanted into mice, these more 
mature cells are capable of producing functional pancreatic beta 
cells. ViaCyte is also the first to show that these further 
differentiated cells can function in vivo following 
cryopreservation, a valuable process step when contemplating 
clinical and commercial application. 
“The tremendous progress in understanding pancreatic cell 
differentiation has enabled development of the first clinical-stage 
therapy with potential to effectively cure type 1 diabetes,” said 
Paul Laikind, Ph.D., president and CEO of ViaCyte. “For a 
number of reasons we believe that the pancreatic progenitor cells 
that are the active component of the VC-01 product candidate 
are better suited for cell replacement therapy. However, the 
current work has expanded our fundamental knowledge of beta 
cell maturation and could lead to further advances for the field.” 
In the News continued from page 27
AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE•AROUNDTHEGLOBE
29
In the News continued on page 30
In addition to demonstrating in vivo functionality, the time to 
functional maturation (i.e., glucose-responsive insulin production) 
following implantation of the more highly differentiated cells was 
compared with that of pancreatic progenitors. The results showed 
no appreciable differences between the two cell populations, 
suggesting that engraftment and acquisition of a robust glucose 
response, not differentiation from progenitor cell to endocrine 
cell, are the rate-limiting steps following implantation. 
In addition to the research progress, ViaCyte continues to build 
its large patent portfolio with three more U.S. patents having 
issued since November 2014. These patents are directed to the 
following: methods for making and enriching pancreatic 
endocrine type cells (U.S. patent no. 9,045,736); scale-up 
technology directed to pluripotent stem cell aggregates in 
suspension in a roller bottle (U.S. patent no. 8,895,300); and 
pancreatic endoderm cell cultures with an ERBB receptor 
tyrosine kinase activating agent (U.S. patent no. 9,109,245). These 
patents bolster and further protect the company’s VC-01 product 
candidate and its cell therapy platform technology. 
ViaCyte’s VC-01 product candidate, comprised of human PEC-
01 pancreatic progenitor cells macroencapsulated in the Encap-
tra® drug delivery system, has previously been demonstrated to 
regulate glucose levels in animal models and is in an ongoing 
clinical trial designed to evaluate safety and efficacy in type 1 
diabetes patients. More information on the phase 1/2 clinical 
trial, called STEP ONE, for Safety, Tolerability, and Efficacy of 
VC-01 Combination Product in Type One Diabetes, can be 
found at www.clinicaltrials.gov. 
ViaCyte is a privately held regenerative medicine company 
focused on developing a novel cell replacement therapy for the 
treatment of diabetes. ViaCyte is conducting a phase 1/2 clinical 
trial of the company’s lead VC-01 product candidate in patients 
with type 1 diabetes who have minimal to no insulin-producing 
beta cell function. ViaCyte’s VC-01 combination product 
candidate is based on the production of pancreatic progenitor 
cells derived from human pluripotent stem cells. These progenitor 
cells are implanted in a durable and retrievable encapsulation 
device. Once implanted and matured, these cells are designed to 
secrete insulin and other hormones in response to blood glucose 
levels. The VC-01 product candidate is being developed as a 
potential long-term diabetes treatment without immune 
suppression, and without risk of hypoglycemia or other diabetes-
related complications. 
ViaCyte is headquartered in San Diego, California, with 
additional operations in Athens, Georgia. The company is funded 
in part by the California Institute for Regenerative Medicine 
(CIRM) and JDRF. For more information please visit www.
viacyte.com. Connect with ViaCyte here: www.twitter.com/
viacyte and www.facebook.com/viacyte.
OncoSec Presents Advancements in Intratumoral Gene 
Electro-Transfer Devices for Immuno-Oncology
PRNewswire: September 9, 2015 – SAN DIEGO, CA, 
U.S.A. – OncoSec Medical Incorporated (“OncoSec”) 
(NASDAQ: ONCS), a company developing DNA-based 
intratumoral cancer immunotherapies, today presented recent 
advancements in the field of electroporation (EP) and the future 
of catheter-based devices to perform minimally invasive 
intratumoral immunotherapy treatment at the First World 
Congress on Electroporation and Pulsed Electric Fields in 
Biology, Medicine and Food & Environmental Technologies in 
Portoroz, Slovenia. 
In a keynote presentation entitled “Advances in Clinical 
Electroporation: Tissue Sensing, Feedback Control, and 
Catheter Technology,” Robert H. Pierce, M.D., chief scientific 
officer, discussed OncoSec’s advances in intratumoral gene 
electro-transfer, using “smart” tissue-sensing technology and the 
development of catheter-based electrodes, enabling treatment of 
deep and visceral tumors.
“We are excited to be presenting our engineering advances at the 
First World Congress,” said Dr. Pierce. “The development of 
minimally invasive electroporation devices capable of high-
efficiency delivery of immunotherapeutic genes into tumors 
located anywhere in the body is critical to establishing 
intratumoral EP-mediated gene therapy as a standard 
therapeutic modality in immuno-oncology.”
OncoSec’s new catheter-based electrodes are designed to be 
compatible with standard medical instrumentation, allowing 
access to deep and visceral tumors, where they are capable of 
anchoring to and treating the tumor using OncoSec’s 
proprietary technology. These all-in-one devices have the ability 
to inject a DNA-based agent, while deploying electrodes to 
perform electroporation in a single procedure. Moreover, these 
devices have an adjustable needle and electrode penetration 
depth allowing clinicians to treat tumors of varying dimensions 
to perform minimally invasive intratumoral immunotherapy.
OncoSec is developing “smart” electroporation technology 
capable of tissue sensing and real-time feedback control of 
electroporation pulse trains in order to attain optimal gene 
transfer and minimal electroporation-mediated tissue damage. 
Dr. Pierce added: “Taken together, these engineering advances 
can enable access and high-efficiency gene delivery to tumors 
throughout the body. This is key as we move forward in 
developing OncoSec’s pipeline of novel intratumoral therapies.”
“Our partnership with Rev.1 Engineering and internal 
bioengineering expertise have allowed OncoSec to enhance our 
ImmunoPulse™ platform and position the company as a leader 
in gene electro-transfer technologies in cancer immunotherapy,” 
said Punit Dhillon, president and CEO of OncoSec. “We are 
also strengthening our intellectual property portfolio in the area 
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of gene and drug delivery via electroporation to reach visceral 
tumors and enhance the uptake of therapeutic agents.”
OncoSec secured an exclusive license for a specific patented 
technology from the University of South Florida Research 
Foundation (USFRF). The patent provides a device and related 
methods to deliver molecules to cells that comprise any tissue. 
The patent includes a catheter-based electrode and methods to 
deliver molecules to cardiac tissue, blood vessels, other tissues/
organs that can be accessed through a luminal tissue, and luminal 
tissues. The device also functions as a non-catheter based 
electrode for performing the same functions. Financial terms of 
this agreement were not disclosed. For more information about 
OncoSec and its technologies, please visit www.oncosec.com.
OncoSec is a biopharmaceutical company developing DNA-based 
intratumoral immunotherapies with an investigational technology, 
ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is 
designed to enhance the local delivery and uptake of DNA-based 
immune-targeting agents, such as IL-12. In phase I and II clinical 
trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety 
profile and evidence of anti-tumor activity in the treatment of 
various skin cancers as well as the potential to initiate a systemic 
immune response. OncoSec’s lead program, ImmunoPulse™ 
IL-12, is currently in phase II development for several indications, 
including metastatic melanoma, squamous cell carcinoma of the 
head and neck (HNSCC), and triple-negative breast cancer 
(TNBC). In addition to ImmunoPulse™ IL-12, the company is 
also identifying and developing new immune-targeting agents for 
use with the ImmunoPulse™ platform. For more information, 
please visit www.oncosec.com.
Specialty Drug Delivery Firm Integral BioSystems LLC 
Receives Phase I SBIR Grant to Develop its Novel 
Ophthalmic Sustained Release Glaucoma Formulation
PRNewswire: September 9, 2015 – BEDFORD, MA, U.S.A. – 
Integral BioSystems LLC has just received a phase I SBIR 
research grant for the development of a bio-engineered, 
preservative free, and biocompatible sustained-release treatment 
for glaucoma, EySite-NanoM™ (patent pending).
Currently, most ophthalmic drugs are administered in the form 
of eye-drops. With a single eye-drop, only about 5% of the drug 
administered is absorbed by ocular tissue, and the rest is lost 
through naso-lacrimal drainage. Additionally, fast drainage of 
eye-drop formulations from the ocular space makes frequent 
administration regimens necessary. This leads to patient 
incompliance due to inconvenience, leading to a lower therapeutic 
value of the treatment.
Most commercial formulations for glaucoma treatment contain a 
commonly used preservative, benzalkonium chloride, which has 
been correlated with ocular toxicity in both in vivo and in vitro 
studies, including corneal neurotoxicity. Chronic use of a 
preservative has been correlated with inflammation of ocular 
tissues. Thus, EySite-NanoM™ leads the way to preservative-free 
strategies for glaucoma treatment in future therapeutic regimens.
EySite-NanoM™ is a sustained-release delivery system designed 
to provide continuous release of its therapeutic anti-glaucoma 
agent to avoid the peak and trough drug levels that occur with 
topical dosing. It can be fairly said that EySite-NanoM™ 
utilizes a sustained release delivery system for front-of-the-eye 
ocular delivery with the dosing advantages of punctal plugs and 
drug-coated contact lenses, without the disadvantages. For 
example, in addition to manufacturing challenges, drug-eluting 
contact lenses impact the vision field with inherent alterations in 
the visual acuity of the lens as the drug depletes, and punctal 
plugs require installation by a clinician. EySite-NanoM™ does 
not interfere with a patient’s field of vision, nor does it have to be 
installed by a clinician.
“This delivery system is transformational and has the potential to 
replace frequent and inefficient eye-drop administration for 
chronic ocular disorders,” says Shikha Barman, Ph.D., chief 
executive officer of Integral BioSystems.
Integral BioSystems is a specialty drug delivery research 
organization that offers an integrated, practical approach to 
formulation development projects for both small molecule and 
large molecule drug candidates. The company offers contract 
services to pharmaceutical companies to develop its drug 
products, through its CMC offerings in analytical method 
development, formulation development, process development, 
scale-up, and technology transfer. The company also partners 
with pharmaceutical companies to co-develop products based on 
its proprietary ophthalmic delivery systems, OcuSurf™ and 
EySite™, both of which are patent pending.
Starpharma Signs Drug Delivery License with 
AstraZeneca
Business Wire: September 7, 2015 – MELBOURNE, 
Australia – Starpharma (ASX: SPL) (OTCQX: SPHRY) today 
announced the signing of a licensing agreement with global phar-
maceutical company AstraZeneca. The agreement enables the de-
velopment and commercialisation by AstraZeneca of compounds 
directed at a defined family of targets using Starpharma’s DEP® 
drug delivery technology. The DEP® platform centres on use of 
Starpharma’s proprietary dendrimers, with the aim of enhancing 
the dosing and efficacy characteristics of pharmaceuticals.
Under the agreement Starpharma is eligible to receive signature 
and milestone payments on one or more AstraZeneca DEP® 
products if they progress through the development pipeline, and 
milestone and royalty payments on any net sales of the resultant 
products. AstraZeneca will fund all development and 
commercialisation costs under the agreement, including ongoing 
and future collaborative work conducted with Starpharma.
Starpharma’s other programs, including the company’s wholly 
owned DEP® docetaxel product, are not negatively impacted by 
this arrangement.
A signature payment of US$2 million (A$2.9 million) became 
payable on execution of the agreement. For the initial product, 
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development and launch milestones could total up to US$64 
million (A$91 million), and sales milestones based on specified 
annual sales levels could total up to US$60 million (A$86 
million). The license agreement allows for additional products to 
be incorporated, with development and regulatory milestone 
payments of up to US$53.3 million (A$76 million), and potential 
sales milestones based on specified annual sales levels for 
qualifying additional products could total up to US$40 million 
(A$57 million). Any AstraZeneca DEP® products would also 
attract tiered royalties on net sales.
“Today’s agreement with AstraZeneca is an exciting development 
for Starpharma and its DEP® platform. It follows a successful 
collaboration in which Starpharma’s DEP® drug delivery 
technology has been applied to an important AstraZeneca 
oncology candidate,” said Dr Jackie Fairley, Starpharma chief 
executive officer.
“The agreement clearly illustrates both the commercial potential 
and platform nature of Starpharma’s DEP® drug delivery 
technology. We estimate that each qualifying product successfully 
commercialised under this agreement could be worth over its life 
around US$450 million (A$643 million) to Starpharma and, 
depending on the range of indications and degree of commercial 
success in the market, potentially significantly more,” Dr Fairley 
added.
“The fact that this deal is structured for multiple products 
underlines the real potential for additional upside for both 
companies. It is worth noting that Starpharma retains all rights 
outside of a well-defined and narrow area of application, meaning 
that its platform remains unencumbered and available for 
licensing in the vast majority of oncology and other applications 
for future deals with other partners.”
Susan Galbraith, head of the Oncology Innovative Medicines 
Unit at AstraZeneca, said: “We already have a long-standing and 
successful working relationship with Starpharma. This license 
agreement will enable us to further harness the DEP® technology 
and evaluate its potential across novel molecules within our 
oncology portfolio.”
Cancer is a leading cause of death worldwide, accounting for 8.2 
million deaths in 2012. The number of new cases is expected to 
rise by about 70% over the next two decades. The global market 
for cancer drugs has reached US$100 billion in annual sales, and 
could reach US$147 billion by 2018, according to a new report 
by the IMS Institute for Healthcare Informatics, a unit of drug 
data provider, IMS Health.
Starpharma’s DEP® technology is used to improve the perfor-
mance of pharmaceuticals. Both preclinical and early clinical data 
have shown DEP® versions of drugs to be superior in a variety of 
ways to the unmodified drugs in currently marketed formula-
tions. Preclinical studies of DEP® conjugates with a number of 
different cancer drugs have already established improved efficacy 
and reduced toxicities compared with marketed versions. 
Starpharma’s lead internal development candidate, DEP® 
docetaxel, continues to demonstrate excellent tolerability and im-
proved pharmacokinetics in the clinic compared with the avail-
able data for its reference drug, Taxotere®. Starpharma’s licensing 
agreement with AstraZeneca focuses on novel compounds, and 
not on unmodified drugs in currently marketed formulations.
Cipla to Acquire 100% of Generic Businesses in the 
United States for $550M
PRNewswire: September 3, 2015 – MUMBAI, India – Cipla, a 
global pharmaceutical company that uses technology and innova-
tion to meet the everyday needs of all patients, today announced 
that its U.K. arm, Cipla EU, has entered into definitive agree-
ments to acquire two U.S.-based companies, InvaGen Pharma-
ceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction 
being subject to certain closing conditions, is valued at $550 mil-
lion and will be an all cash transaction. The combined revenue 
from these transactions is over $200 million for the year ended 
December 2014 and over $225 million in LTM June 2015. This 
acquisition, which is the second landmark acquisition in Cipla’s 80 
years of history, will give the company scale in the U.S. generics 
market through a wide ranging product portfolio in CNS, CVS, 
anti-infectives, diabetes, as well as other value-added generics. In-
vaGen offers a large capacity manufacturing base in Hauppauge, 
New York, and a skilled U.S.-based R&D organization, Cipla’s 
first such presence in the United States.
The acquisition of InvaGen pharmaceuticals also provides Cipla 
with about 40 approved ANDAs, 32 marketed products, and 30 
pipeline products that are expected to be approved over the next 
four years. They represent a balanced, diversified, and growing 
portfolio targeting highly attractive, large, and niche markets. In 
addition, InvaGen has filed five first-to-file products that 
represent a market size of ~$8 billion in revenue by 2018. Dosage 
forms include immediate release, modified release, and extended 
release tablets and capsules. With a manufacturing footprint of 
~350,000 square feet of GMP area, InvaGen has three units 
located in Long Island, New York, with a total production 
capacity of 12 billion tablets and capsules per annum and about 
500 employees. This acquisition further provides Cipla with an 
access to large wholesalers and retailers in the United States.
The acquisition of Exelan Pharmaceuticals provides Cipla access 
to the government and institutional market in the United States 
through Exelan’s deep expertise, engagement, and experienced 
management team in the business. 
Commenting on the acquisition, Mr. Subhanu Saxena, M.D., 
global CEO of Cipla Limited, said: “This investment is in line 
with Cipla’s strategy to grow Cipla’s share in the U.S. 
pharmaceutical market. We see InvaGen as a strong strategic fit 
with a relevant diverse portfolio as well as a strong market and 
customer presence. With a local manufacturing facility, Cipla can 
further strengthen its presence and commitment to serve patients 
in the country.”
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Tim Crew, CEO North America and director of Cipla USA Inc., 
added: “We are delighted with the immediate and substantial rel-
evance this combination brings to Cipla in the United States. We 
are committed to an orderly transition process with customers and 
InvaGen to ensure the ongoing continuity of a high quality and 
reliable supply to our customers and their patients.” 
Dr. Sudhakar Vidiyala, president and CEO, InvaGen 
Pharmaceuticals Inc., commented: “This is an exciting o
pportunity for InvaGen to join with Cipla. InvaGen brings an 
experienced team and good manufacturing capabilities to the 
partnership. We are confident that the combination of InvaGen 
and Cipla will significantly enhance the product portfolio offer-
ing, including specialty products, to the U.S. patients and will 
give InvaGen access to Cipla’s global expertise and presence.”
Cipla is a global pharmaceutical company that uses cutting-edge 
technology and innovation to meet the everyday needs of all 
patients. For around 80 years, Cipla has emerged as one of the 
most respected pharmaceutical names in India as well as across 
more than 150 countries. Our portfolio includes over 1,500 
products across wide range of therapeutic categories with one 
quality standard globally.
While delivering a long-term sustainable business, Cipla 
recognises its duty to provide affordable medicines. Cipla’s 
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emphasis on access for patients was recognised globally for the 
pioneering role played in HIV/AIDS treatment as the first 
pharmaceutical company to provide a triple combination anti-
retroviral (ARV) in Africa at less than a dollar a day and thereby 
treating many millions of patients since 2001. Cipla’s research 
and development focuses on developing innovative products and 
drug delivery systems.
Through a comprehensive partnership model, Cipla has been 
dedicated to providing access to medicines at an affordable price 
for over 30 years in the United States.
Cipla USA own label was launched in January 2015. Cipla has 
executed over 20 U.S. partnerships and currently has over 40 
commercialized products in the United States. The company has 
supported the development of more than 150 ANDAs and has 
received 75+ final approvals in addition to two NDAs approved 
and marketed in the United States.
Cipla USA brings a variety of technologies to the U.S. markets 
in order to keep its ongoing commitment to provide access to 
high quality complex products at affordable prices. For more 
information on Cipla, please visit www.cipla.com and 
www.ciplausa.com. n
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